Organizing and Scientific Committees ........................................ p. 3
Keynote Speakers .................................................................................................. p. 4
Lifetime Achievement Award ................................................................................ p. 6
Program at a glance ............................................................................................... p. 7
  – Wednesday, October 24 ................................................................. p. 9
  – Thursday, October 25 ....................................................................... p. 10
  – Friday, October 26 ........................................................................... p. 14
  – Saturday, October 27 ................................................................. p. 18
Poster presentations .......................................................................................... p. 21
Theme 1. Clinical trials: Methodology ............................................................... p. 22-24
Theme 2. Clinical trials: Results ........................................................................ p. 25-27
Theme 3. Clinical trials: Imaging ....................................................................... p. 28-29
Theme 4. Clinical trials: Biomarkers including plasma ................................ p. 30-34
Theme 7. Behavioral disorders and clinical trials .......................................... p. 43
Theme 8. Health economics and clinical trials ............................................ p. 44
Theme 9. Epidemiology and clinical trials ...................................................... p. 45-46
Theme 11. New therapies and clinical trials ................................................. p. 48-49
Privileged partners .............................................................................................. p. 50
General information .......................................................................................... p. 51
CTAD Scientific Committee

Susan ABUSHAKRA (San Francisco)
Paul AISEN (San Diego)
Kaj BLENNOW (Molndal)
Merce BOADA (Barcelona)
Maria CARRILLO (Chicago)
Mony John DE LEON (New York)
Steven DEKOSKY (Miami)
Bruno DUBOIS (Paris)
Howard FELDMAN (San Diego)
Nick FOX (London)
Giovanni B. FRISONI (Brescia, Geneva)
Lutz FROELICH (Mannheim)
Serge GAUTHIER (Montreal)
Ezio GICOBINI (Geneva)
Michael GRUNDMANN (San Diego)
Harald HAMPEL (Paris)
Takeshi IWATSUBO (Tokyo)
Ara KHACHATURIAN (Washington DC)
Zaven KHACHATURIAN (Washington DC)
Virginia LEE (Philadelphia)

Constantine G. LYKETSOS (Baltimore)
José Luis MOLINUEVO (Barcelona)
Jean-Marc ORGOGOZO (Bordeaux)
Ronald PETERSEN (Minnesotta)
Craig W. RITCHIE (Edinburgh)
Augustin RUIZ (Barcelona)
Robert RISSMAN (San Diego)
Stephen SALLOWAY (Providence)
Rachel SCHINDLER (New York)
Philip SCHELTENS (Amsterdam)
Lon SCHNEIDER (Los Angeles)
Eric SIEMERS (Philadelphia)
Peter SNYDER (Rhode Island)
Reisa SPERLING (Boston)
Yaakov SHER (New York)
Jacques TOUCHON (Montpellier)
John TROJANOWSKI (Philadelphia)
Bruno VELLAS (Toulouse)
Michael W. WEINER (San Francisco)
Bengt WINBLAD (Stockholm)
«Blood biomarkers for AD clinical trials»
Randall Bateman, MD, PhD

Charles F. and Joanne Knight Distinguished Professor of Neurology at the Washington University School of Medicine, St. Louis, USA

Dr. Randall Bateman, the Charles F. and Joanne Knight Distinguished Professor of Neurology at the Washington University School of Medicine, is the PI of the Dominantly Inherited Alzheimer Network (DIAN) and DIAN Trials Unit which coordinates with pharmaceutical, regulatory, and patient advocacy groups for clinical trials in dominantly inherited Alzheimer’s disease. Dr. Bateman’s laboratory investigates the causes and future diagnosis and treatments of Alzheimer’s disease utilizing a wide variety of assays and techniques. His lab measures the pathophysiology of Alzheimer’s disease in humans utilizing amyloid-beta, apolipoprotein E, APP, and tau protein kinetics. His work has been supported by the NIH, foundations, and Pharma, and he has consulted for the FDA, NIH and Pharma. He has served as a co-investigator on multiple multi-site trials including ADNI and AD clinical trials. Dr. Bateman mentors junior faculty members, fellows, and students, all successful in their desired career trajectory. His contributions have been recognized with awards from the AlzForum Community, Alzheimer’s Association (Zenith Award), Scientific American, the Glenn Award for Aging Research, and the MetLife Foundation.

«What have we learned from Aducanumab?»
Samantha Budd Haeberlein, PhD

Vice President of Alzheimer’s Disease Discovery & Development, Biogen, Boston, USA

Samantha Budd Haeberlein, Ph.D., joined Biogen in February 2015 as Vice President of Alzheimer’s Disease Discovery & Development. Dr Budd Haeberlein was previously Vice President of Translational Science at AstraZeneca where for fifteen years she led multi-disciplinary teams and functions across Research, Strategy, Translational Medicine and Clinical Development in the US, Canada and Sweden. Dr Budd Haeberlein has a BSc (Hons.) and PhD in Biochemistry from the University of Dundee in Scotland, and conducted research at Brigham & Women’s Hospital Harvard Medical School in Boston, and at The Burnham Institute in San Diego.

«Anti-Tau Treatments: Potential, Challenges, and Progress»
Lennart Muche, MD

Director of the Gladstone Institute of Neurological Disease and Joseph B. Martin Distinguished Professor of Neuroscience and Professor of Neurology at the University of California, San Francisco (UCSF), USA

Dr. Muche is the founding director of the Gladstone Institute of Neurological Disease and holds joint appointments as the Joseph B. Martin Distinguished Professor of Neuroscience and Professor of Neurology at the University of California, San Francisco. He trained at the Free University Berlin, the Georg-August University and the Max Planck Institute for Biophysical Chemistry in Göttingen, the Cleveland Clinic, the Massachusetts General Hospital and Harvard Medical School, and The Scripps Research Institute. Dr. Muche’s research focuses on mechanisms that result in functional deficits in Alzheimer’s disease and other cognitive disorders. He has generated informative experimental models of these conditions and used them to identify novel strategies to prevent neurological decline. For his contributions, Dr. Muche has received the Potamkin Prize, MetLife Foundation Award for Medical Research, Kalid Iqbal Lifetime Achievement Award, Zenith Award, American Pacesetter Award, MERIT Award, and an Award for Excellence in Direct Teaching and Mentoring. He is a member of the American Neurological Association and the Association of American Physicians, chairs the Senate of the German Center for Neurodegenerative Diseases, and has served on the Medical and Scientific Advisory Council of the Alzheimer’s Association and on the National Advisory Council on Aging for the NIH.
«How BIG and GOOD Data are revolutionizing Neurodegenerative Disease Research»

Cristina Sampaio, MD, PhD  
Chief Medical Officer, CHDI Foundation, Princeton, USA

Professor Cristina Sampaio joined CHDI Foundation as Chief Clinical Officer 6 years ago. She also holds the position of Professor of Clinical Pharmacology and Therapeutics at Faculdade de Medicina de Lisboa (currently on unpaid leave). At CHDI Professor Sampaio oversees an extensive portfolio of clinical projects ranging from experimental medicine, through biomarker and rating scale development to support drug development activities, to the development and maintenance of a global clinical research platform, Enroll-HD. Professor Sampaio spent 25 years of her career in academia where her primary research interests centered on clinical research methodology, clinical trial design, and related aspects of meta-research applied to movement disorders. Together with several colleagues she founded the Cochrane Movement Disorders Group (MovDisCRG) and became its coordinating editor in 1996, a position that she has shared with Professor Joao Costa from 2013 to 2018. She is now an Editor of The MovDisCRG. Professor Sampaio published 170 peer review papers and book chapters. From 1998 to 2011, Professor Sampaio was a member of the Committee on Human Medicinal Products and the Scientific Advice Working Party at the European Medicines Agency. During this period, she had a very active role in the development of the standards of regulatory science for CNS medicinal products in the European Union. She was rapporteur, coordinator, or assessor of over 400 medicinal products files submitted to EMA for licensing or scientific advice and she coordinated the first clinical biomarker qualification in the EU. Professor Sampaio obtained her MD in 1986 and her PhD in clinical pharmacology in 1997 from the University of Lisbon. She is a board-certified clinical pharmacologist, receiving neurological training in the Neurology department of Hospital St Maria in Lisbon. She was a staff member of the Movement Disorders Clinic from 1988 to 2011, President of the Portuguese Movement Disorders Society 2008-2012, and Chair of the Evidence-based Medicine Committee of the International Parkinson and Movement Disorder Society 2010-2014.

«Combination therapy in AD»

Daniel M. Skovronsky, MD, PhD  
Senior Vice President of Clinical and Product Development at Eli Lilly and Company, Indianapolis, USA

Dr. Daniel M. Skovronsky, serves as Senior Vice President of Clinical and Product Development at Eli Lilly and Company. Dr. Skovronsky is responsible for developing the Lilly pipeline of molecules. He was the Founder, Chief Executive Officer and President at Avid Radiopharmaceuticals Inc. Dr. Skovronsky founded Avid Radiopharmaceuticals in 2004. Prior to establishing the firm, he served as Scientific Director of High Throughput Screening and Drug Discovery at the Center for Neurodegenerative Disease Research at the University of Pennsylvania. Dr. Skovronsky served as Vice President of Radiopharmaceutical Development at Theracor Pharmaceuticals. He served as a Member of Advisory Board of Safeguard Sciences, Inc., until October 21, 2015 and previously served as a Member of its Life Sciences Advisory Board. Dr. Skovronsky serves as a Director of Avid Radiopharmaceuticals, Inc. He has more than 20 peer-reviewed publications and two NIH-funded grants on Alzheimer’s disease research. He is the recipient of numerous scientific and business awards and was named by the Philadelphia Business Journal as one of their Forty under Forty business leaders in the region. Dr. Skovronsky received the Ernst & Young Entrepreneur Of The Year 2009 Award in the Emerging Company category, which recognizes outstanding entrepreneurs who are building and leading dynamic, growing businesses. He trained as a resident in Pathology and completed a Fellowship in Neuropathology at the Hospital of the University of Pennsylvania. Dr. Skovronsky received his MD and PhD from the University of Pennsylvania and did BS degree in Molecular Biochemistry at Yale University.
Rachelle Doody MD, PhD is the Global Head of Neurodegeneration in Pharma Development, Neuroscience for Roche Pharmaceutical Company and its US entity, Genentech. Prior to joining Genentech/Roche in September, 2016, Dr. Doody was the Effie Marie Cain Chair in Alzheimer’s Disease Research at Baylor College of Medicine, in Houston, Texas where she founded and directed the Alzheimer’s Disease and Memory Disorders Center over a period of 27 years.

While at Baylor, she published over 200 original research articles, served on the steering committees for the National Institutes of Health-funded Alzheimer’s Disease Cooperative Study (ADCS) and Alzheimer’s Disease Neuroimaging Initiative (ADNI), and the executive committee for the Alzheimer’s Therapeutic Research Institute (ATRI).

In her role as a practicing Neurologist, Dr. Doody was elected to Best Doctors in America from 1996-2016. She has received many awards from professional and civic groups, including Distinguished Alumni Award from Rice University in 2009 and Distinguished Faculty Award from Baylor College of Medicine in 2011.
Wednesday, October 24

4.00 - 4.30 p.m.  Opening Ceremony and CTAD Lifetime Achievement Award

4.30 - 5.00 p.m.  Keynote 1 - Blood biomarkers for AD clinical trials

5.00 - 5.50 p.m.  Symposium 1 - APECS trial of the BACE1 inhibitor verubecestat for prodromal Alzheimer’s disease

5.50 - 6.40 p.m.  Emerging Results From Other BACE Inhibitor Trials Discussion of BACEi Trial Findings: Challenges and Opportunities

6.40 - 7.00 p.m.  Late breaking oral communication

Thursday, October 25

8.30 - 10.00 a.m.  Oral communications

10.00 - 10.30 a.m.  Coffee break and poster session

10.30 - 11.30 a.m.  Symposium 2 - Is BACE1 a suitable drug target for prevention and treatment of Alzheimer’s disease?

11.30 - 12.30 p.m.  Oral communications

12.30 - 1.30 p.m.  Lunch and poster session

1.30 - 2.00 p.m.  Keynote 2 - What have we learned from Aducanumab?

2.00 - 2.30 p.m.  Late breaking oral communications

2.30 - 3.30 p.m.  Symposium 3 - Clinical and Biomarker Updates from BAN2401 Study 201 in Early AD

3.30 - 4.30 p.m.  Oral communications

4.30 - 5.00 p.m.  Coffee break and poster session

5.00 - 6.00 p.m.  Symposium 4 - Aβ blood based test as surrogate markers of cortical amyloid pathology for clinical trials on Alzheimer’s disease.
Friday, October 26

8.30 - 10.00 a.m. | Oral communications
10.00 - 10.30 a.m. | Coffee break and poster session
10.30 - 11.00 a.m. | Keynote 3 - Anti-Tau treatments: Potential, challenges, and progress
11.00 - 11.30 a.m. | Late Breaking communications
11.30 - 12.30 p.m. | Symposium 5 - Towards the Development of a Complete Solution for Patients with Alzheimer’s Disease (AD)
12.30 - 1.30 p.m. | Lunch and poster session
1.30 - 2.45 p.m. | Oral communications
2.45 - 4.00 p.m. | Late Breaking communications
4.00 - 4.30 p.m. | Coffee break and poster session
4.30 - 5.00 p.m. | Keynote 4 - Combination therapy in AD
5.00 - 6.00 p.m. | Symposium 6 - Endpoints for early Alzheimer’s disease clinical trials: Interpretation and application of the draft FDA guidance

Saturday, October 27

8.30 - 9.15 a.m. | Presentation and panel discussion: AMBAR (Alzheimer’s Management By Albumin Replacement) Phase IIb/III Results
9.15 - 9.45 a.m. | Keynote 5 - How BIG and GOOD Data are revolutionizing neurodegenerative disease research
9.45 - 10.15 a.m. | Coffee break and poster session
10.15 - 11.15 a.m. | Oral communications
11.15 - 12.15 p.m. | Symposium 7 - Disclosure of Alzheimer’s risk biomarkers to cognitively normal older adults
12.15 - 1.15 p.m. | Lunch and poster session
1.15 - 3.45 p.m. | Oral communications
3.45 p.m. | End of conference
Opening Ceremony and CTAD Lifetime Achievement Award

Jacques Touchon, Paul Aisen, Bruno Vellass, Mila Weiner, Merce Boada, Jose Luis Molinuevo. The recipient of this year's CTAD Lifetime Achievement Award is Rachelle S. Doody M.D., Ph.D. Global Head of Neurodegeneration, Roche, Basel - Switzerland for her work dedicated to academic and industrial research in AD clinical trials.

Keynote 1
Blood biomarkers for AD clinical trials

Introduction by: Bruno Vellas, MD, PhD
Randall Bateman, MD, PhD - Charles F. and Joanne Knight Distinguished Professor of Neurology at the Washington University School of Medicine, St. Louis, USA

Symposium 1 - APECS trial of the BACE1 inhibitor verubecestat for prodromal Alzheimer's disease

Symposium moderator: Jeffrey L. Cummings, MD, ScD, Cleveland Clinic, Las Vegas, NV, USA

Communication 1: Results from the APECS trial
Michael F. Egan, MD1, Tiffany Voss, MD, Yuhi Muhai, MD, James Kost, PhD1, Paul S Aisen, MD1, Jeffrey L. Cummings, MD, ScD1, Pierre N. Tariot, MD1, Bruno Vellass, MD, PhD1, Christopher H. van Dych, MD1, Ying Zhang, PhD1, Wen Li, PhD1, Christine Furteh, BS1, Erin Mahoney, BA1, Lyn Harper Mozley, PhD1, Yi Mo, PhD1, Cyrille Sur, PhD1, David Michelson, MD1
1Merck & Co., Inc., Kenilworth, NJ, USA, 2University of Southern California, San Diego, CA, USA
3Cleveland Clinic, Las Vegas, NV, USA

Communication 2: Panel discussion
Paul S. Aisen, MD1, Maria C. Carrillo, PhD1, Pierre N. Tariot, MD1, Bruno Vellass, MD, PhD1
1University of Southern California, San Diego, CA, USA
3The Alzheimer Association, Chicago, IL, USA

Emerging Results From Other BACE Inhibitor Trials
Discussion of BACEi Trial Findings: Challenges and Opportunities

CoChairs: Reisa Sperling, MD, Brigham & Women’s Hospital, Maria C. Carrillo, PhD, Alzheimer’s Association

Presentation 1: Preliminary analyses of data from an ongoing trial of atabecestat in preclinical Alzheimer's disease.
Gary Romano, MD, PhD1, Randi Jansen R&D, USA

Presentation 2: LB1 - Results from the phase 2 NAVIGATE-AD clinical trial evaluating LY3202626 BACE inhibitor in patients with mild Alzheimer’s disease dementia.
Albert C. Lo1, Cynthia Duggan Evans1, Michele Mancini1, Qin Lin, Hong Wang1, Peng Liu1, Sergey Shcherbinin1, Ming Lu1, Arnaud Charil1, Brian A Willis1, Michael Irizarry1
1Eli Lilly and Company, Indianapolis, IN, USA
4Eli Lilly and Company, Indianapolis IN, USA
3Eli Lilly and Company, Indianapolis IN, USA

Panel discussion: Reisa Sperling, MD, Brigham & Women’s Hospital, Maria C. Carrillo, PhD, Alzheimer’s Association, Marth Mintun, MD, Eli Lilly & Co, Michael Egan, MD, Merck & Co., Gary Romano, MD, Dohren Jansen R&D, Ana Graf, MD, Novartis & Amgen, Inc, Johan Luthman, MD, Eisai Co, Ltd, John Sim, MD, Lilly/AZ Alliance

Late Breaking Oral communication

Chair: Maria Carrillo, PhD

6.40 - 7.00 p.m. LB2 - TOMMORROW: a trial to delay the onset of MCI due to AD and qualify a genetic biomarker algorithm: topline results
Robert Alexander, MD1, Daniel K. Burns, PhD2, Kathleen A. Welsh-Bohmer, PhD3, Carl Chiang, PhD3, Meredith Culp, BS4, Janet O’Neil, MBA4, Brenda L. Plassman, PhD5, Craig Metz, PhD5, Deborah Varbrough, MS, MBA4, Jingtao Wu, PhD5, Rebecca Evans, MD6, Kurt Budur, MD6, Stephen K. Brannan, MD6, Ann M. Saunders, PhD5, Emiliangelo Ratti, PhD6 for the TOMMORROW Study Investigators
1Takeda Development Center Americas, Inc, Cambridge, MA, USA, 2Zinfandel Pharmaceuticals, Inc, Durham, NC, USA, 3Duke University Bryan ADRC, Durham, NC, USA, 4Walgreens BioPharma, Madison, WI, USA, 5Takeda Development Center Americas, Inc, Deerfield, IL, USA
8.30 - 10.00 a.m. Oral communications

Chairs: Suzanne Craft, MD, PhD and Rachel Schindler, PhD

8.30 - 8.45 a.m. OC1 - Phase 2a trial of AZD0530 evaluating 18F-FDG PET, safety, and tolerability in mild Alzheimer’s dementia
Christopher H. van Dyck, MD1, Haahon B. Nygaard, MD, PhD2, Kewei Chen, PhD1, Michael C. Donohue, PhD3, Rema Raman, PhD2, Robert A. Rissman, PhD2, James B. Brewer, MD, PhD3, Robert A. Koepppe, PhD2, Tiffany W. Chow, MD4, Michael S. Rafi, MD4, R. Scott Turner, MD, PhD3, Jeffrey A. Kaye, MD3, Seth A. Gale, MD3, Eric M. Reiman, MD3, Paul S. Aisen, MD4, Stephen M. Strittmatter, MD, PhD3

1Yale University School of Medicine, New Haven, USA 2The University of British Columbia, Vancouver, Canada 3Banner Alzheimer’s Institute, Phoenix, USA 4Alzheimer’s Therapeutic Research Institute, University of Southern California, San Diego, USA 5University of California San Diego, La Jolla, USA 6University of Michigan, Ann Arbor, USA 7Georgetown University, Washington, DC, USA 8Oregon Health & Science University, Portland, USA 9Harvard Medical School, Boston, USA

8.45 - 9.00 a.m. OC2 - Primary results from a phase II/III trial of intranasal insulin: A novel multi-target molecule and delivery mode for AD therapeutics
Suzanne Craft, PhD1, Rema Raman, PhD2, Tiffany Chow, MD2, Michael S. Rafii, MD2, Robert A. Rissman, PhD3, James B. Brewer, MD3, Michael Donohue, PhD3, Chung-Kai Sun, MS3, Kelly Harless3, Devon Gessert3, Paul S. Aisen, MD2

1Wake Forest School of Medicine, Winston-Salem, USA 2University of Southern California, Los Angeles, USA 3University of California, San Diego, USA

9.00 - 9.15 a.m. OC3 - Phase 3 clinical trial for a novel and multi-targeted oligosaccharide in patients with mild-moderate AD in China
Shifu Xiao, MD1, Zhenxin Zhang, MD1, Meiyu Geng, PhD1, GV-971 Study Group

1Department of Gerontology, Shanghai Mental Health Center, Shanghai Jiao Tong University, Shanghai, China 2Peking Union Medical College Hospital, Beijing, China 3State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China

9.15 - 9.30 a.m. OC4 - Active Anti-amyloid Immunotherapy with UB-311 Vaccine: Design, baseline data and study update of a Phase IIa, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Parallel-Group, Multicenter Study
Ajay Verma, Hui Jing Yu, Hui-Chen Chen, and Chang Yi Wang on behalf of the UB-311 Phase IIa Study Team

United Neuroscience, Inc. Hauppauge, NY, USA

9.30 - 9.45 a.m. OC5 - Elenbecestat in MCI-to-moderate Alzheimer’s disease: Safety and effectiveness as measured by amyloid PET and the ADCOMS clinical endpoints
Shau Yu Lynch, PhD1, June Kaplow, PhD1, Jim Zhao, MS, MM1, Shobha Dhadda, PhD1, Johan Luthman, PhD, DDS1, Bruce Albaia, PhD1

1Eisai Inc., Woodcliff Lake, NJ, USA

9.45 - 10.00 a.m. OC6 - ALLOPREGNANOLONE regenerative therapeutic for mild cognitive impairment and mild Alzheimer’s disease; Phase Ib/2a outcomes update
Roberta D. Brinton, PhD1, Gerson D. Hernandez, MD, MPH1, Naoko Kono, MPH1, Claudia M. Lopez, BS1, Christine Solinshy, PhD1, Kathleen Rodgers, PhD1, Jin Gahm, PhD1, Dogu Aydogan, PhD1, Yonggang Shi, PhD1, Sonia Pawluczyn, MD1, Meng Law, MD1, Wendy Mach, PhD1, Lon Schneider, MD, MS1

Center for Innovation in Brain Science, University of Arizona, Tucson, Arizona, USA 2Department of Preventive Medicine, University of Southern California, Los Angeles, CA, USA 3School of Pharmacy, University of Southern California, Los Angeles, CA, USA 4USC Institute for Neuroimaging and Informatics, University of Southern California, Los Angeles, CA, USA 5Department of Psychiatry & The Behavioral Sciences, Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA 6Department of Radiology, University of Southern California, Los Angeles, CA, USA

10.00 - 10.30 a.m. Coffee break and poster session
Symposium 2
Is BACE1 a suitable drug target for prevention and treatment of Alzheimer’s disease?

Symposium moderator: Randall J. Bateman, MD, Department of Neurology, St. Louis, MO, USA

Communication 1: Physiological substrates of BACE1: safety issues or biomarkers?
Stefan F. Lichtenthaler, PhD German Center for Neurodegenerative Diseases (DZNE) and Technical University of Munich (TUM), Germany

Communication 2: Secretase inhibitors in AD prevention trials: optimizing success and mitigating risk.
Eric McDade, DO, Department of Neurology, St. Louis, MO, USA

Communication 3: Considerations and lessons learned for the design and implementation of AD clinical trials evaluating BACE inhibitors.
Bruce Albala, PhD and Johan Luthman, PhD; Eisai, Inc.; NJ, USA

Oral communications

Chair: Lon Schneider, MD

11.30 - 11.45 a.m.
OC7 - Impact of Amyloid PET on the management of cognitively impaired patients: Results from the IDEAS study
Gil D. Rabinovici,1 Constantine Gatsonis,2 Charles Appar,3 Kishan Chaudhary,1 Ilana Gareen,2 Lucy Hanna,2 James Hendrix,4 Bruce E. Hillner,3 Cynthia Olson,3 Orit Lesman-Seiger,1 Justin Romanoff,2 Barry A. Siegel,1 Rachel A. Whitmer,1 Maria C. Carrillo,6 on behalf of the IDEAS investigators.
1Department of Neurology, University of California San Francisco, 2Center for Statistical Sciences, Brown University, 3American College of Radiology, 4Alzheimer’s Association, 5Department of Medicine, Virginia Commonwealth University, 6Division of Research, Kaiser Permanente

11.45 - 12.00 p.m.
OC8 - Safety and efficacy of estrogen receptor-β targeted PhytoSERM formulation for cognitive complaints and vasomotor symptoms: Phase Ib/2a trial outcomes
Lon S. Schneider, MD1, Gerson Hernandez MD MPH2, Liqin Zhao PhD3, Sonia Pawluczyk MD,4 Wendy J. Mach, PhD1, Roberta D. Brinton PhD2
1Keck School of Medicine of the University of Southern California, Los Angeles, USA, 2University of Arizona, Center for Innovation in Brain Science, Tucson, USA, 3University of Kansas, USA

12.00 - 12.15 p.m.
OC9 - Interim safety and efficacy results of pilot trial of GM-CSF/sargramostim in mild to moderate AD
Huntington Potter, PhD Jonathan H. Woodcock, Timothy Boyd, Stefan H. Sillau, Thomas Borges, Brianne M. Bettcher, Joseph Daniels
Rocky Mountain Alzheimer’s Disease Center, Department of Neurology University of Colorado School of Medicine

12.15 - 12.30 p.m.
OC10 - Untangled – peptide-based inhibitors of tau aggregation as a potential treatment for Alzheimer’s disease
David Allsop PhD1,2, Anthony Aggidis MSc1, Nigel Fullwood PhD1, Mark Taylor PhD2, Penny Fouls Phd2, Shoona Vincent PhD2, Mark Dale MD2
1Division of Biomedical and Life Sciences, Faculty of Health and Medicine, Lancaster University, Lancaster, UK, 2Peptide Innovations Limited, Affiliated Company of MAC Research, Blackpool, UK

12.30 - 1.30 p.m.
Lunch and poster session

1.30 - 2.00 p.m.
Keynote 2
What have we learned from Aducanumab?

Introduction: Jacques Touchon, MD, PhD
Samantha Budd Haerlein, PhD - Vice President of Alzheimer’s Disease Discovery & Development, Biogen, Boston, USA
Late Breaking Oral communications

2.00 - 2.15 p.m.  LB3 - Lu AF20513, an active immunotherapy against amyloid beta, in development for patients in early stages of Alzheimer’s disease
Bjørn Sperling, MD1, Lars Østergaard Pedersen, PhD1, Neli Boneva, MD1, Dorthe Daugaard, MD1, Yudong Zhao, PhD1
1H. Lundbeck A/S, Valley, Denmark

2.15 - 2.30 p.m.  LB4 - Predictors of [18F]flortaucipir (tau) load in Alzheimer’s disease and other neurodegenerative disorders
Oskar Hansson, MD, PhD2,4, Gil D. Rabinovici MD, PhD3, Chul H. Lyoo, MD, PhD4 & Rih Ossenkoppele, PhD4,5
1Lund University, Clinical Memory Research Unit, Lund, Sweden, 2Memory Clinic, Ståne University Hospital, Malmö, Sweden, 3Department of Neurology, University of California San Francisco, San Francisco, USA, 4Memory and Aging Center, 5Department of Neurology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea, 6VU University Medical Center, Department of Neurology and Alzheimer Center, Amsterdam Neuroscience, Amsterdam, the Netherlands

Symposium 3
Clinical and Biomarker Updates from BAN2401 Study 201 in Early AD

3.30 - 3.45 p.m.  OC11 - Safety and efficacy of lemborexant for sleep-wake rhythm disorder and Alzheimer’s disease dementia
Margaret Moline, PhD1, Mohammad Bsharat, PhD1, Manuel Kemethofer, MSc2, Gleb Filippov, MD, PhD1, Naoki Kubota, MPharm1, Patricia Murphy, PhD1
1Eisai, Inc., Woodcliff Lake, USA, 2The Siesta Group, Vienna, Austria, 3Eisai Co. Ltd., Tokyo, Japan

3.45 - 4.00 p.m.  OC12 - Tau PET imaging as a screening tool for clinical trials of disease modifying therapies
Adam S Fleisher1, Michael J Pontecorvo2, Michael D Devous2, Ming Lu2, Sergey Shcherbinin1, Anupa K Arora2, Mark A Mintun2
1Eli Lilly & Co, Indianapolis, IN, USA, 2Avid Radiopharmaceuticals, Inc., Philadelphia, PA, USA

4.00 - 4.15 p.m.  OC13 - BACE inhibition by verubecestat produces a rapid, non-progressive reduction in brain and hippocampal volume in Alzheimer’s disease
Cyrille Sur, PhD1, James Kost, PhD1, David Scott, PhD1, Katarzyna Adamczuk, PhD1, Nick C Fox, PhD1, Jeffrey Cummings, MD, ScD1, Pierre Tariot, MD1, Paul Aisen, MD1, Bruno Vellas, MD, PhD1, Tiffini Voss, MD1, Yultu Multai, MD1, David Michelson, MD1, Michael Egan, MD1
1Merck & Co., Inc., Kenilworth, NJ, USA, 2Bristol-Myers Squibb, New York, NY, USA, 3University College London, London, UK, 4Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA, 5Banner Alzheimer’s Institute, Phoenix, AZ, USA, 6University of California San Diego, San Diego, CA, USA, 7Gerontopole, Toulouse University Hospital, Toulouse, France
Symposium 4

**Aβ blood based test as surrogate markers of cortical amyloid pathology for clinical trials on Alzheimer’s disease.**

**Moderator:** Pedro Pesini PhD, Araclon Biotech-Grifols, Spain.

**Communication 1:** Developing Aβ blood based test into pre-screening tools for clinical trials in early stages of AD

Victor L. Villemagne, M.D. Dept of Molecular Imaging & Therapy, Austin Health, Dept of Medicine, The University of Melbourne.

**Communication 2:** Plasma ratio of total Aβ42 to total Aβ40 in amnestic MCI patients is associated with FDG-PET, amyloid-PET, CSF and the risk of progression to AD dementia.

Anne Fagan PhD, Washington University, Saint Louis, Missouri.

**Communication 3:** Total Aβ42 to total Aβ40 as a biomarker of cortical amyloid burden in subjects with subjective memory complaints.

Agustín Ruiz MD PhD. Research Director, Research Center and Memory Clinic. Fundació ACE. Institut Català de Neurociències Aplicades. Universitat Internacional de Catalunya (UIC), Barcelona, Spain.
8.30 - 10.00 a.m. Oral communications
Chairs: Laura D. Baker, PhD and Ana Graf, MD

8.30 - 8.45 a.m. OC15 - Cocoa supplement and multivitamin outcomes study of cognitive function (cosmos-mind): design of a large randomized clinical trial
Laura D. Baker, PhD1, Mark A. Espeland, PhD1, Stephen R. Rapp, PhD1, Sally A, Shumaher, PhD, Sarah A, Gaussoin, MSI, Howard D. Sesso, ScD1, JoAnn E. Manson, MD, DrPH1
Wake Forest School of Medicine, Winston-Salem, USA, 1B Brigham and Women's Hospital, Harvard Medical School, Boston, USA

8.45 - 9.00 a.m. OC16 - Rationale and design of a prospective, randomized, double-blind, dose-comparison safety and tolerability study of GRF6019 in mild-to-moderate Alzheimer’s disease
Jonas Hannestad, MD PhD 1, Ian Gallager, PhD1, Katie Koborsi, MS1, S. Saltura Minami, PhD1, Darby Stephens, MBA1, Viktoria Kheifets, PhD1, Steven Braithwaite, PhD1
1Alkahest, Inc., San Carlos, USA

9.00 - 9.15 a.m. OC17 - Machine learning algorithm helps identify non-diagnosed prodromal Alzheimer’s disease patients in general population
Olga Uspenskaya-Cadoz1, Chaitanya Alamuri1, Sam Khinda1, Yuliya Nigmatullina1, Carolina Rubel1, Lanhui Wang1, Mengting Yang1, Tao Cao1, Nithil Kaya1
1IQVIA CNS Center of Excellence, 1IQVIA Analytics Center of Excellence, 1IQVIA Project Leadership

9.15 - 9.30 a.m. OC18 - ABBV-8E12, a humanized anti-tau monoclonal antibody, for treating early Alzheimer’s disease: Updated design and baseline characteristics of phase 2 study
Hana Florian, MD1, Steven E. Arnold, MD2, Randall J. Bateman, MD2, Joel B. Braunstein, MD, MBA1, Kumar Budur, MD1, Diana R. Kerwin, MD1, Holly Soares, PhD1, Deli Wang, PhD1, David M. Holtzman, MD3
1AbbVie, Inc., North Chicago, IL, USA, 2Massachusetts General Hospital, Boston, MA, USA, 3Washington University, St. Louis, MO, USA

9.30 - 9.45 a.m. OC19 - Assessment of clinical meaningfulness of endpoints in the Generation Program by the Insights to Model Alzheimer’s Progression in real life (IMAP) study
A. Graf1, V. Risson1, S. Tzveletis2, A. Gustavsson3, V. Bezyalt, A. Caputol, P.N. Tariot4, J.B. Langbaum4, C. Lopez Lopez1, V. Vigilletta2
1Novartis Pharma AG, 2Amgen, Inc., 3Quantify Research, 4Banner Alzheimer’s Institute

9.45 - 10.00 a.m. OC20 - Characterizing clinical severity among biomarker positive individuals: Applying the 2018 NIA-AA research criteria for Alzheimer’s disease to four large study cohorts.
Roos J. Jutten, MSc1, Rebecca E. Amariglio, PhD2,3, Gad A. Marshall, MD, PhD2,3, Dorene M. Rentz, PhD2,3, Wiesje M. Van der Flier, PhD, Philip Scheltens, MD, PhD1, Keith A. Johnson2,4, Reisa A. Sperling, MD2,3, PhD, Sietske A.M. Sikkes, PhD1,4, Kathryn V. Papp, PhD2
1Alzheimer Center, VU University Medical Center, Amsterdam, The Netherlands, 2Department of Neurology, Brigham and Women’s Hospital, Harvard Medical School, Boston MA, USA, 3Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston MA, USA, 4Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston MA, USA

10.00 - 10.30 a.m. Coffee break and poster session

10.30 - 11.00 a.m. Keynote 3
Anti-Tau treatments: Potential, challenges, and progress
Introduction: Paul Aisen, MD
Lennart Mucke, MD Director of the Gladstone Institute of Neurological Disease and Joseph B. Martin Distinguished Professor of Neuroscience and Professor of Neurology at the University of California, San Francisco (UCSF), USA
Late Breaking communication and panel discussion

**LB5 - 18F-AV-1451-A16: A clinico-pathological study of the correspondence between flortaucipir PET imaging and post-mortem assessment of tau pathology**

Mark A. Minun1, Adam S. Fleisher1, Michael D. Devous2, Ming Lu2, Anupa K. Arora2, Thomas G. Beach2, Thomas J. Montine1, Michael J. Pontecorvo2

1Eli Lilly and Company, Indianapolis, IN, USA, 2Avid Radiopharmaceuticals, Inc., Philadelphia, PA, USA, 3Civin Laboratory for Neuropathology, Banner Sun Health Research Institute, Phoenix, AZ, USA, 4Department of Pathology, Stanford University, Stanford, CA, USA

Symposium 5
Towards the Development of a Complete Solution for Patients with Alzheimer’s Disease (AD)

**Moderator:** Rachelle Doody, MD, PhD1,2
1Genentech, Inc., South San Francisco, CA, USA, 2F. Hoffmann-La Roche Ltd, Basel, Switzerland

**Communication 1:** Self-detection of cognitive problems: benefits and challenges of online and digital tools

Mary Sano, PhD1,2
1Director, Alzheimer’s Disease Research Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA, 2Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY, USA

**Communication 2:** Enhancing earlier and more reliable diagnosis of AD through the use of emerging biomarkers

Christopher van Dych, MD1,2
1Alzheimer’s Disease Research Unit, Yale University School of Medicine, New Haven, CT, USA, 2Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA, 3Department of Neurology, Yale University School of Medicine, New Haven, CT, USA

**Communication 3:** Moving towards combination therapies for disease modification in AD

Dennis J. Selkoe, MD1,2
1Ann Romney Center for Neurologic Diseases, Brigham and Women’s Hospital, Boston, MA, USA, 2Harvard Medical School, Boston, MA, USA

Lunch and poster session

Oral communications

**Chairs:** Sandrine Andrieu, MD, PhD and Gregory Klein, PhD

**OC21 - Extension and validation of an amyloid staging model: Associations with clinical measures**

Lyduine Collij, MSc1, Fiona Heeman, MSc1, Gemma Salvadó Blasco, MSc2, Elies Konijnenberg, MSc2, Anouk den Braber, PhD2, Maqsood Yaqub, PhD1, Pieter Jelle Visser, MD, PhD1, Alle Meije Winit, Ir, PhD1, Philip Scheltens, MD, PhD2, Ronald Boellaard, PhD1, Bart N.M. van Berckel, MD, PhD1, Juan Domingo Gispert López, PhD2, Mark Schmidt, MD, PhD2, Frederik Barkhof, MD, PhD1,6, Isadora Lopes Alves, PhD1

1Dept. of Radiology and Nuclear Medicine, VU University Medical Center, Amsterdam, The Netherlands, 2BarcelonaBeta Brain Research Center, Barcelona, Spain, 3Alzheimer Center and Dept. of Neurology, VU University Medical Center, Amsterdam, The Netherlands, 4Institute of Neurology and Healthcare Engineering, University College London, London, United Kingdom

**OC22 - Twenty-four-month amyloid PET results of the gantenerumab high-dose SCarlet and Marguerite RoAD open-label extension studies**

Gregory Klein, PhD2, Paul Delmar, PhD1, Cassten Hofmann, PhD1, Danielle Abi-Saab, PsyD1, Mirjana Andjelkovic, PhD2, Smiljana Ristic, MD2, Nicola Voyle, PhD1, Jacob Hesterman, PhD1, John Seibyl1, Ken Marek1, Ferenc Martenyi, MD1, Monika Baudler, PhD1, Paulo Fontoura, MD, PhD1, Rachelle Doody, MD, PhD2

1Roche Pharma Research and Early Development, Basel, Switzerland, 2Roche / Genentech Product Development, Neuroscience, Basel, Switzerland, 3Roche Products Ltd, Welwyn Garden City, UK, 4InnCRO, LLC, Boston, MA, USA
Friday, October 26

2.00 - 2.15 p.m.  
**OC23 - Multi-domain interventions to prevent dementia: from FINGER to World-Wide FINGERS**  
Mia Kivipelto 1,2,3, On behalf of the World-Wide FINGERS network  
1Karolinska Institutet, Department of Clinical Geriatrics, Center for Alzheimer Research, Stockholm, Sweden; 2University of Eastern Finland, Institute of Clinical Medicine/Neurology, Kuopio, Finland; 3Imperial College London, NEA, School of Public Health, UK

2.15 - 2.30 p.m.  
**OC24 - Identifying risk of cognitive decline in Mild Cognitive Impairment for population enrichment of clinical trials**  
Christian Dansereau 1, PhD, Maor Zaltzhendler 1, MEng, Angela Tam 1, MSc, Pedro Rosa-Neto 1, MD, PhD, Serge Gauthier 1, MD, Pierre Bellec 2,3, PhD  
1Perceiv Research Inc., Montreal, CAN; 2Centre de Recherche de l'Institut Universitaire de Gériatrie de Montréal, CAN; 3Douglas Mental Health University Institute, McGill University, CAN; 4Department of Computer Science and Operations Research, University of Montreal, CAN

2.30 - 2.45 p.m.  
**OC25 - Study update on XanADu: Phase II study of XanamemTM in subjects with mild dementia due to Alzheimer’s disease**  
Craig Ritchie, MD, PhD, Centre for Dementia Prevention, University of Edinburgh, UK

2.45 - 3.00 p.m.  
**LB6 - Age and ApoE genotype-specific population frequencies of cerebral β-amyloidosis and hippocampal atrophy among cognitively normal individuals in CHARIOT-PRO**  
Hany Rofael, MD, PhD 1, Gerald Noah 1, MD, Luc Bracoud 1, MSc 2, Nandini Ragavan 3, PhD, Ziad Saad 3, PhD, Sinstein 3, Robert Brashier 3, David Scott 3, PhD, Joel Schaeer 3, PhD, Celeste de Jager 3, PhD, Chi Udeh-Momoh 3, PhD, the Alzheimer’s Disease Neuroimaging Initiative (ADNI), and Lefkos Middleton 5  
1Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA; 2vTv Therapeutics LLC, High Point, NC, USA; 3Cato Research LTD, Durham, NC, USA; 4Cintrex LLC, Longboat Key, FL, USA

3.00 - 3.15 p.m.  
**LB7 - Safety and efficacy results from the phase 3, multicenter, 18-month STEADFAST trial of azeliragon in participants with mild Alzheimer’s disease**  
Marwan Sabbagh 1, Imogene Dunn 1, PhD, Ann Gooch 1, PhD, Tom Soeder 1, MS, Karl Kieburtz 1, MD, MPH, Carmen Valcarce 1, PhD, Larry D Altsieli 1, PhD, 2, Aaron H Burstein 2, PharmacD 1, PhD, 2,3, 4,5  
1Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA; 2vTv Therapeutics LLC, High Point, NC, USA; 3Cato Research LTD, Durham, NC, USA; 4Cintrex LLC, Longboat Key, FL, USA

3.15 - 3.30 p.m.  
**LB8 - Aducanumab titration dosing regimen: 36-month analyses from PRIME, a Phase 1b study in patients with early Alzheimer’s disease**  
Samantha Budd Haeberlein 1, Carmen Castrillo-Vigueria 1, PhD, Taniele Chen 1, PhD, John O’Gorman 1, PhD, Raj Rajagovindan 1, PhD, Dahnshaben Patel 1, PhD, Philipp von Rosenstiel 1, MD, Guanfang Wang 1, PhD, Spyros Chalkias 1, MD, LeAnne Storhord 1, PharmacD, Claudia Prada 1, Dr, Christoph Hoch 1, MD, Roger M Nitsch 1, MD, Alfred Sandrock 1, MD, PhD 1  
1Biogen, Cambridge, MA, USA; 2Biogen, Maidenhead, UK; 3Cyell, Cambridge, MA, USA; 4Neumimmune, Schlieren-Zurich, and University of Zurich, Switzerland

3.30 - 3.45 p.m.  
**LB9 - Longitudinal 148-Week Extension Study for ANAVEX®2-73 Phase 2a Alzheimer’s Disease Demonstrates Maintained Activities of Daily Living Score (ADCS-ADL) and Reduced Cognitive Decline (MMSE) for Patient Cohort on Higher Drug Concentration and Confirms Role of Patient Selection Biomarkers**  
Harald Hampel 1, MD, PhD, Mohammad Afshar 1, MD, PhD, Frédéric Parmentier 1, PhD, Coralie Williams 1, MSc, Adrien Etcheto 1, MSc, Federico Goodsaid 2, PhD, Christopher U Missling 2, PhD  
1Department of Neurology, Sorbonne University, Paris, France; 2Anavex Life Sciences Corp., New York, NY

3.45 - 4.00 p.m.  
**LB10 - Predictive performance of CSF and imaging AD biomarkers in ADNI/GO/2 MCI participants using the NIA-AA research framework**  
Leslie M Shaw 1, PhD, Michael Figlitschi 1, PhD, Susan Landau 1, PhD, William Jagust 2, MD, Clifford R Jack 3, MD, Paul S Aisen 4, MD, Ronald C Petersen 4, MD, Michael W Weiner 5, MD, John Q Trojanowski 4, MD, PhD  
1University of Pennsylvania, Philadelphia, USA; 2University of California, Berkeley, Berkeley, USA; 3Mayo Clinic, Rochester, USA; 4University of Southern California, San Diego, USA; 5University of California, San Francisco, San Francisco, USA
Friday, October 26

4.00 - 4.30 p.m. Coffee break and poster session

4.30 - 5.00 p.m. Keynote 4

Keynote 4
Combination therapy in AD

Introduction: Jeffrey Cummings, MD, PhD
Daniel M. Shovronsky, MD, PhD - Senior Vice President of Clinical and Product Development at Eli Lilly and Company, Indianapolis, USA

4.30 - 5.00 p.m. Keynote 4

Combination therapy in AD

Introduction: Jeffrey Cummings, MD, PhD
Daniel M. Shovronsky, MD, PhD - Senior Vice President of Clinical and Product Development at Eli Lilly and Company, Indianapolis, USA

4.30 - 5.00 p.m. Keynote 4

Combination therapy in AD

Introduction: Jeffrey Cummings, MD, PhD
Daniel M. Shovronsky, MD, PhD - Senior Vice President of Clinical and Product Development at Eli Lilly and Company, Indianapolis, USA

5.00 - 6.00 p.m. Symposium 6

Symposium 6
Endpoints for early Alzheimer’s disease clinical trials: Interpretation and application of the draft FDA guidance

Symposium moderator: Eric Siemers, MD, Cogstate Ltd, New Haven, CT, USA

Communication 1: Clinical Endpoints in Stage 1, 2 and 3 Disease
Reisa Sperling, MD, Ronald C. Petersen, MD, PhD, Gary Roman, MD, PhD, Paul Maruff, PhD
Division of Neurology, Brigham and Women’s Hospital, Boston, MA, USA, Department of Neurology, Mayo Clinic, Rochester, MN, USA, Janssen R&D, Titusville, NJ, USA

Communication 2: Biomarkers in Stage 1, 2 and 3 Disease
Samantha Budd Haeberlein PhD, Jose Luis Molinuevo, MD, PhD, Christopher C. Rowe, PhD, Maria C. Carrillo PhD
Biogen, Cambridge, MA, USA, BarcelonaBeta Brain Research Center, Pasqual Maragall Foundation and Hospital Clinic-IDIBAPS, Barcelona, Spain, Department of Molecular Imaging, Austin Health, University of Melbourne, Melbourne, Australia, Alzheimer’s Association, Chicago, IL, USA, Department of Radiology, Mayo Clinic, Rochester, MN, USA

Communication 3: Approaches to Establishing the Meaningfulness of Treatment Effects
Chris J. Edgar, PhD, George Vradenburg, JD, Jason Hassenstab, PhD
Cogstate Ltd, London, UK, UsAgainstAlzheimer’s and Alzheimer’s Disease Patient and Caregiver Engagement (AD PACE), Chevy Chase, MD, USA, Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA
8.30 - 9.15 a.m.
Presentation and panel discussion:
**AMBAR (Alzheimer’s Management By Albumin Replacement) Phase IIb/III Results**

**Presentation** by Antonio Páez MD, Grifols S.A., Barcelona, Spain

**Followed by** Panel Discussion with:

**Panel discussion moderator:** Jeffrey L. Cummings, MD, ScD, Cleveland Clinic, Las Vegas, NV, USA

- Mercè Boada MD, PhD, Fundació ACE, Universitat Internacional de Catalunya, Barcelona, Spain
- Oscar L. Lopez MD, PhD, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
- Zbigniew M. Szczepiorkowski, MD, PhD, Dartmouth Hitchcock Medical Center, Lebanon, NH, USA
- Bruno Vellas, MD, PhD, University Hospital, Toulouse, France

9.15 - 9.45 a.m.
**Keynote 5**
How BIG and GOOD Data are revolutionizing neurodegenerative disease research

**Introduction:** Bruno Vellas, MD, PhD

*Cristina Sampaio, MD, PhD - Chief Medical Officer, CHDI Foundation, Princeton, USA*

9.45 - 10.15 a.m.
Coffee break and poster session

10.15 - 11.15 a.m.
**Oral communications**

10.15 - 10.30 a.m.
**OC26 - First longitudinal evaluation of the tau tracer [18F]MK-6240 for the use in clinical trials**

Tharick A. Pascoal MD, Sulantha Mathotaarachchi MSc, Mira Chamoun PhD, Joseph Therriault BSc, Robert Hopewell PhD, Gassan Massarweh PhD, Andrea L. Benedet, MSc, BSc, Min Su Kang, Jean-Paul Soucy MD, Serge Gauthier, MD, Pedro Rosa-Neto, MD, PhD

1Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, McGill University, Montreal, Canada, 2Montreal Neurological Institute, McGill University, Montreal, Canada

10.30 - 10.45 a.m.
**OC27 - Implementation of the NIA-AA research framework: toward a biological definition of Alzheimer’s disease in AIBL**

Samantha C Burnham, Preciosa M Coloma, Qiao-Xing Li, Steven Collins, Greg Savage, Simon Laws, James Doeche, Paul Maruff, Ralph N Martins, David Ames, Christopher C Rowe, Colin L Masters, Victor L Villemagne

1eHealth, CSIRO, Parkville, VIC, Australia, 2School of Medical Sciences, Edith Cowan University, Joondalup, Australia, 3Product Development Personalised Health Care - Data Science, F. Hoffmann-La Roche Ltd, Basel, Switzerland, 4The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Victoria, Australia, 5Department of Pathology, University of Melbourne, Parkville, Australia, 6Macquarie University, Sydney, Australia, 7eHealth, CSIRO, Herston, QLD, Australia, 8Cogstate Ltd, Melbourne, Australia, 9Macquarie University, North Ryde, Australia, 10National Ageing Research Institute, Melbourne, Australia, 11Austral Health, Melbourne, Australia, Brain Health, Las Vegas, NV, USA

10.45 - 11.00 a.m.
**OC28 - The neuroprotective effect of a new photobiomodulation technique on Aβ25-35 peptide-induced toxicity dramatically impact gut microbiota dysbiosis**

Jacques Touchon, MD, PhD, Laura Auboyer, PhD, Johann Meunier, PhD, Laura Ceolin, PhD, François J. Roman, PhD, Rémy Burcelin, PhD, Guillaume J. Blivet, MS

1Montpellier University, France, 2INSERM U1061, Montpellier, France, 3REGENLIFE SAS, Montpellier, France, 4Amylgen SAS, Montpellier, France, 5Vaxioneer SAS, Labège, France
Disclosure of Alzheimer’s risk biomarkers to cognitively normal older adults

**Communication 1:** “Not just a colonoscopy” – cognitively normal older adults reactions to learning an amyloid PET result

Jason Karlawish, MD1, Kristin Harkins, MPH2, Emily Largent, JD, PhD3, Pamela Sanhar, PhD4, Jeff Burns, MD5, David Sulzer, MD6, Joshua Grill, PhD6

1Departments of Medicine, Medical Ethics and Health Policy, and Neurology, University of Pennsylvania, Philadelphia, PA, USA, 2Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA, 3Department of Medical Ethics and Health Policy, University of Pennsylvania, Philadelphia, PA, USA, 4Department of Neurology, University of Kansas, Kansas City, KS, USA, 5Department of Psychiatry, University of California, Los Angeles, CA, USA, 6Department of Psychiatry and Human Behavior, University of California, Irvine, CA, USA

**Communication 2:** Remote genetic counseling and disclosure of APOE genotype within the Generation study 1

Elisabeth McCarty Wood, MS1, Cara Cacioppo, MS1, Neeraja Reddy, MS2, Dare Henry-Moss, MPH1, Demetrios Ofidis, BS1, Brian L. Egleston, PhD3, Jason Karlawish, MD1, J Scott Roberts, PhD1, Scott Kim, MD, PhD1, Carolyn Langlois, MA6, Eric M. Reiman, MD1, Pierre N. Tariot, MD1, Jessica B. Langbaum, PhD1, Angela R. Bradbury, MD1

1University of Pennsylvania, Philadelphia, PA, USA, 2Mapmygenome, Navi Mumbai, India, 3Fox Chase Cancer Center, Philadelphia, PA, USA, 4University of Michigan, Ann Arbor, MI, USA, 5National Institutes of Health, Bethesda, MD, USA, 6Banner Alzheimer’s Institute, Phoenix, AZ, USA

**Communication 3:** Application of an APOE disclosure model at a clinical trial site and the impact of dual disclosure of amyloid PET results

Louisa Thompson, PhD1,2, Athene Lee, PhD1,2, Meghan Collier, PhD2, Danielle Goldfarb, MD, BRITANY Dawson, FNP2, Stephen Salloway, MD1,2, Jessica Alber, PhD1,2

1Warren Alpert Medical School of Brown University, Providence, RI, USA, 2Butler Hospital, Providence, RI, USA

ORAL COMMUNICATIONS:

**OC30** - Adult conditional BACE1 knock out mice exhibit axonal organization defects in the hippocampus

Robert Vassar, PhD Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, USA

**OC31** - TRC-PAD: Accelerating participant recruitment in AD clinical trials through innovation

Gustavo A. Jimenez-Maggiora, MBA1, Rema Raman, PhD2, Michael S. Rafii, MD, PhD2, Reisa Anne Sperling, MD2,2, Jeffrey Lee Cummings, MD2,2, Paul S. Aisen, MD1

1Alzheimer’s Therapeutics Research Institute, University of Southern California, San Diego, CA, USA, 2Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA, 3Department of Radiology, Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA, 4Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA
■ **Theme 1. Clinical trials: Methodology**  
  P2, P4, P5, P59, P61, P82, P86, P90 to P101 and LBP1 to LBP12 

■ **Theme 2. Clinical trials: Results**  
  P7, P12, P13, P15, P16, P18, P36, P80, P109 to P112 and LBP1 to LBP21 

■ **Theme 3. Clinical trials: Imaging**  
  P10, P35, P62, P76, P113 to P124 and LBP21 to LBP24 

■ **Theme 4. Clinical trials: Biomarkers including plasma**  
  P1, P4, P22, P28, P30, P39, P44, P57, P64 to P66, P73, P78, P81, P125 to P139 and LBP25 to LBP40 

■ **Theme 5. Clinical trials: Cognitive and functional endpoints**  
  P2, P3, P8, P9, P19, P25 to P27, P53, P67, P69, P71, P74, P77, P83, P140 to P149 and LBP41 to LBP46 

■ **Theme 6. Cognitive assessment and clinical trials**  
  P6, P14, P24, P29, P33, P34, P41, P42, P47 to P52, P55, P63, P68, P70, P72, P75, P87 to P89, P150 to P159 and LBP58 to LBP52 

■ **Theme 7. Behavioral disorders and clinical trials**  
  P32, P37, P43, P163 and LBP53 

■ **Theme 8. Health economics and clinical trials**  
  P17, P40, P58, P164 

■ **Theme 9. Epidemiology and clinical trials**  
  P27, P38, P46, P165 to P168 and LBP54 to LBP56 

■ **Theme 10. Clinical Trials: Animal Models**  
  P102 to P104 and LBP58 

■ **Theme 11. New therapies and clinical trials**  
  P5, P11, P20, P23, P56, P60, P79, P84, P85, P105 to P108 and LBP59 to LBP62
Theme 1. Clinical trials: Methodology

P21 - Patterns of MMSE subtest scores in amyloid-positive and -negative participants in J-ADNI
Ryoko Ihara, MD, K., Kazushi Suzuki, MD, A., Tsatsuki Matsuoka, MD, T., Takeshi Iwatsubo, MD, T., the Japanese Alzheimer’s Disease Neuroimaging Initiative
The Unit for Early and Exploratory Clinical Development, The University of Tokyo Hospital, Tokyo, Japan, Department of Neurology, The University of Tokyo, Tokyo, Japan, Department of Neuropathology, The University of Tokyo, Tokyo, Japan

P45 - Innovations in care community-based recruitment to clinical trial research
Jacobo Mintzer, MD, MBA, Mike Splaine, Erin Becht, MPH
Research and Innovation Center, Roper St. Francis, Charleston, SC, USA, Managing Partner, Recruitment, Partners LLC, Columbia, MD, USA, Managing Partner, Recruitment Partners LLC, Columbia, MD, USA, Director of Site Recruitment and Management, Recruitment Partners LLC, Columbia, MD, USA

P54 - Validation of Alzheimer’s biomarkers: β-amyloid 1-42 and total tau in CSF by automated CLEIA on lumipulse g 1200 platform
Satya Nandana Narla, Amanda Dider, Ming Hu, Tina LV, Yuan Xueling and Martine Florent
Immunology Department, Covance Central Laboratories, Indianapolis, USA, Immunology Department, Covance Central Laboratories, Shanghai, China

P59 - The impact of frailty on the risk of screen failure in randomized controlled trials on Alzheimer’s disease
Alessandro Trebbastoni, MD, PhD, Marco Canevelli, MD, PhD, Giuseppe Bruno, MD, Carlo de Lena, MD, Letizia Imbriano, Fabrizia D’Antonio, MD, Laura Pieroni
Department of Human Neuroscience, “Sapienza” University of Rome, Italy

P61 - Concierge site services: site-specific support and capacity development improves recruitment performance
Jacobo Mintzer, MD, MBA, Mike Splaine, Erin Becht, MPH
Research and Innovation Center, Roper St. Francis, Charleston, SC, USA, Managing Partner, Recruitment, Partners LLC, Columbia, MD, USA, Managing Partner, Recruitment Partners LLC, Columbia, MD, USA, Director of Site Recruitment and Management, Recruitment Partners LLC, Columbia, MD, USA

P82 - Meotis3rc: Efficient network for clinical research on cognitive disorders in North and Pas-de-Calais
Catherine Adnet-Bonne, MD, Brigitte Leprin, Laura Brouin, MD, Florence Pasquier, MD, PhD
Meotis, Centre Hospitalier Universitaire de Lille, France, Neurology Department, Centre Hospitalier Universitaire de Lille, France, Excellence Laboratory DISTALZ, Inserm U1171, Unv Lille

P86 - Recruiting older Latinos in senior centers with a culturally tailored Alzheimer’s presentation
Jaime Perales, PhD, MPH, W Todd Moore, MS, Mariana Ramirez, LMSW, Linda Lara, BA, Erica Davis, BA, Jason Resendes, MS, Eric D Vidoni, PhD
University of Kansas Medical Center, Kansas, USA, Guadalup Center, Kansas City, USA, Don Bosco Senior Center, Kansas City, USA, Latinos Against Alzheimer’s Coalition, Chey Chase, USA, L1171, Unv Lille

P90 - REVERSE-SD: ongoing phase-2b study of neflamapimod designed in accordance with emerging scientific and regulatory concepts of early Alzheimer’s disease (AD)
John Alam, Kelly Blackburn, Niels Prins, Philip Scheltens
EIP Pharma Inc., Cambridge, MA, USA, Department of Neurology and Alzheimer Centre, VU University Medical Centre, Amsterdam, NL, Brain Research Center, Amsterdam, NL

P91 - A Phase 2b/3, Double-Blind, Randomized, Placebo-Controlled 48-Week Trial of ANAVEX® 2-73 for the Treatment of Early Alzheimer’s Disease Together with Precision Medicine Genetic Biomarkers
Stephen MacFarlane, MBBS FRANZCP, Michael Kornhauser BPharm, Ella Modini BSc, Harald Hampel, MD, PhD, Stephan Toutain MS, Christopher Missling PhD
HammondCare Dementia Centre, NSW, Australia, Carbone University, Paris, France, Anavex Life Sciences Corp, New York, USA

P92 - Impact of genetic testing on clinical trial participation and subject selection, a pilot study
Mariana Cajet-Berman, MD, PhD, Jessica Branning, Vishnunarathra Nitra, MS
Biology Research, Orlando, FL, USA, Clinical Cloud, Orlando, FL, USA

P93 - The impact of Transcranial Magnetic Stimulation on diagnostic confidence in patients with Alzheimer Disease eligible for clinical trials
Alberto Benussi, MD, Antonella Alberici, MD, Clarissa Ferrari, MD, Valentina Canioni, MD, Valentina Dell’Era, MD, Rosanna Turroni, MS, Maria Sofia Cotelli, MD, Giuliano Binetti, MD, Barbara Paghera, MD, Giacomo Koch, MD, Barbara Bononi, MD, Alessandro Padovani, MD, PhD
*These authors contributed equally to this work.
Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy, IRCCS Centro San Giovanni di Dio Fatabenefratelli, Brescia, Italy, Department of Neuroscience, Psychology, Drug Research and Child Health, University of Florence, Florence, Italy, Neurology Unit, Ospedale Vallecarnonica, Esine, Brescia, Italy, Nuclear Medicine Unit, Spedali Civili Brescia, Brescia, Italy, Non Invasive Brain Stimulation Unit, IRCCS Santa Lucia Foundation, Rome, Italy, Stroke Unit, Policlinico Tor Vergata, Rome, Italy
P94 - Applying patient-centred insights to optimize protocol design and increase biomarker collection acceptability in AD trials

Kenneth Stanley1, Carolina Rubel1, Lynne Hughes1

IQVIA Project Leadership Unit

P95 - CSF biomarkers outcomes in the ETHERAL AD study

Harald Hampel1,2, Carlos Buesa3, Tamara Maes4, Mabel Arevalo5, Michele Lufino6, Roger Bulloch7,8

1AXA Research Fund & Sorbonne University Chair, Paris, France, 2Sorbonne University, CIG n°21, Alzheimer Precision Medicine (APM), AP-HP, Pité-Salpêtrière Hospital, Paris, France, 3Brain & Spine Institute (ICM), INSERM U 1127, CNRS UMR 7225 Paris, France, 4Institute of Memory and Alzheimer’s Disease (IM2A), Department of Neurology, Pité-Salpêtrière Hospital, AP-HP, Paris, France, 5Oryzon Genomics SA, Barcelona, Spain

P96 - EMIF-AD: A unique pan-European platform for large-scale research on biomarkers and risk factors for Alzheimer’s Disease

Preciosa M Colona1, Stephanie J. B. Vos2, Isabella Bos2, Andy Simmons3, Rih Vandenberghe4, Philip Scheltens5, José Luis Molinuevo6,7, Flavio Nobili7, Sebastiaan Engelborghs1,8, Giovanni Frisoni3,4, Gaël Chetelat1,2, Albert Lloë4, Anders Wallin1, Julius Popp1,2,11, Pablo Martinez-Lage8,9, Cornelia Thier10, Pieter Jelle Visser3,4,11, Mark F Gordon8,9, Gerald Nervi10

1Personalised Health Care, Data Science, F. Hoffmann-La Roche AG, Basel, Switzerland, 2Department of Psychiatry and Neuropsychology, Alzheimer Center Limburg, Maastricht University, Maastricht, the Netherlands, 3Institute of Psychiatry, Kings College, London, UK, 4University Hospital Leuven, Leuven, Belgium, 5Alzheimer Center, VU University Medical Center, Amsterdam, the Netherlands, 6Alzheimer’s disease & other cognitive disorders unit, Hospital Clinic-IDIBAPS, Barcelona, Spain, 7Barcelona Beta Brain Research Center, Fundació Pasqual Maragall, Barcelona, Spain, 8Clinical Neurology, Department of Neurosciences (DINOCM), University of Genoa and IRCCS Polyclinic San Martino Hospital, Genoa, Italy, 9Department of Neurology and Memory Clinic, Hospital Neurològic Anxoairu ZNA Middelheim and Hoge Beuken, Anoetxu, Belgium, 10Reference Center for Biological Markers of Dementia (BRCDEM), Institute Born-Bunge, University of Antwerp, Anxoetxu, Belgium, 11University of Geneva, Geneva, Switzerland, 12IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy, 13Inserm, Inserm UMR-S U1237, Université de Caen-Normandie, GIP Cyceron, Caen, France, 14Department of Psychiatry, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, 15University of Gothenburg, Sahlgrenska Academy, Institute of Neuroscience and Physiology, Section for Psychiatry and Neurochemistry, Gothenburg, Sweden, 16Geriatric Psychiatry, Department of Mental Health and Psychiatry, Geneva University Hospitals, Switzerland, 17Department of Psychiatry, University Hospital of Lausanne, Lausanne, Switzerland, 18CITA-Alzheimer Foundation, San Sebastian, Spain, 19Teva Pharmaceuticals, Malvern, PA, USA, 20Janssen Pharmaceutical Research and Development, Titusville, NJ, USA

P97 - Using transcription phenotypes to utilise basket trial methodology from oncology to create new targets in CNS disorders

Roger Bulloch1, David Rotllant2, Michele Lufino3, Cristina Mascaro3, Carlos Buesa4, Tamara Maes4, Sonia Gutierrez5, Marta Valverde5, Tony Ramos5

1Oryzon Genomics, Barcelona, Spain, 2Vall D’Hebron Hospital, Barcelona, Spain

P98 - Can online registers with small amounts of phenotypic data reduce screen failure rates in Alzheimer’s disease trials?

Piers Kotting1, MBA1, Kris Beicher2, Adam Smith2, Clare Shaw, PhD2

1University of Exeter Medical School, Exeter, UK, 2University of Leeds, Leeds, UK, 3Institute of Neurology, University College London, London, UK

P99 - Trial design of the GRADUATE studies: Phase III, randomized, placebo-controlled studies evaluating gantenerumab in patients with early Alzheimer’s disease

Smiljana Ristic1, MD, Mercè Boada, MD, PhD2, Nathalie Pross, PhD2, Danielle Abi-Saab, PsyD2, Szoﬁa Bullain, MD2, Mirjana Andjelkovic, PhD2, Paul Delmar, PhD2, Carsten Hofmann, PhD2, Alison Searle, BSc2, Monika Baudler, PhD2, Paolo Fontoura, MD, PhD2, Rachelle Doody, MD, PhD2

1AXA Research Fund & Sorbonne University Chair, Paris, France, 2Sorbonne University, GRC n° 21, Alzheimer Precision Medicine (APM), AP-HP, Pité-Salpêtrière Hospital, Paris, France, 3Brain & Spine Institute (ICM), INSERM U 1127, CNRS UMR 7225 Paris, France, 4Institute of Memory and Alzheimer’s Disease (IM2A), Department of Neurology, Pité-Salpêtrière Hospital, AP-HP, Paris, France, 5Oryzon Genomics SA, Barcelona, Spain

P100 - The effects of participant characteristics and selection criteria on Alzheimer disease clinical trial outcomes

Richard E. Kennedy, MD, PhD1, Guoqiao Wang, PhD2, Machenzie E. Fowler, MPH1, Gary R. Cutter, PhD1, Lon S. Schneider, MD, MS2

1Department of Medicine, University of Alabama at Birmingham, USA, 2Division of Biostatistics, Washington University, St. Louis, USA, 3Department of Epidemiology, University of Alabama at Birmingham, USA, 4Department of Biostatistics, University of Alabama at Birmingham, USA, 5Department of Psychiatry and the Behavioral Sciences, Keck School of Medicine of the University of Southern California, Los Angeles, USA

P101 - Study enrollment and Alzheimer’s disease pathology in relation to cohort type and participant characteristics in the EPAD Registry

Lisa Vermunt1, MD1, Graciela Muniz-Terrera, PhD2,3,4, Lea ter Meulen, MSc1, Colin Veal, PhD1, José Luis Molinuevo, MD, PhD1, Pierre-Jean Ousset1, MD2, Niels D Prins, MD, PhD4, David Porteous, PhD1, Craig W Ritchie, PhD1, Philip Scheltens, MD, PhD1, Gerald Luscan, MSc5, Anthony J Broothes, PhD1, Pieter Jelle Visser, MD, PhD5

1VU University Medical Center, Amsterdam, Netherlands, 2University of Edinburgh, Edinburgh, Scotland, 3University of Victoria, Victoria, Canada, 4University of Cambridge, Cambridge, England, 5University of Leicester, Leicester, England, 6Barcelona Beta Research Center, Barcelona, Spain, 7CIBM, Université Paris Descartes, INSERM U 972, Toulouse, France, 8Brain Research Center, Amsterdam, Netherlands, 9Pfizer, Paris, France, 10Oryzon Genomics, Barcelona, Spain, 11Maastricht University, Maastricht, Netherlands

P102 - The effects of participant characteristics and selection criteria on Alzheimer disease clinical trial outcomes

Richard E. Kennedy, MD, PhD1, Guoqiao Wang, PhD2, Machenzie E. Fowler, MPH1, Gary R. Cutter, PhD1, Lon S. Schneider, MD, MS2

1Department of Medicine, University of Alabama at Birmingham, USA, 2Division of Biostatistics, Washington University, St. Louis, USA, 3Department of Epidemiology, University of Alabama at Birmingham, USA, 4Department of Biostatistics, University of Alabama at Birmingham, USA, 5Department of Psychiatry and the Behavioral Sciences, Keck School of Medicine of the University of Southern California, Los Angeles, USA
Late Breaking Posters

LBP1 - Harnessing the power of big data and technology innovations to advance Alzheimer’s disease clinical development
Olga Uspenskaya-Cadoz1, Yuliya Nigmatullina2, Kenneth Stanley3, Chaitanya Alamuri1, Penny Randall1, Sam Khinda1, Lanhui Wang2, Mengting Yang3, Carolina Rubel1, Lynne Hughes1, Tao Cao1, Michelle O’Keefe1, Nithil Kayal1
1IQVIA CNS Center of Excellence; 2IQVIA Analytics Center of Excellence; 3IQVIA Project Leadership

LBP2 - Course correction in A4: implementation of dose escalation
Karen Holdridge, MPH1, Roy Yaari, MD1, Brian A. Willis, PhD1, Isabella Velona, MS1, Paul Aisen, MD2, Reisa Sperling, MD3
1Eli Lilly and Company, Indianapolis, USA, 2University of Southern California, San Diego, USA, 3Brigham and Women’s Hospital, Boston, USA

LBP3 - Dose escalation in the DIAN-TU solanezumab arm. Was solanezumab in mild to moderate AD dementia too little, too late?
Karen Holdridge, MPH1, Roy Yaari, MD1, Brian A. Willis, PhD1, Isabella Velona, MS1, Susan Mills1, Randall Bateman2
1Eli Lilly and Company, Indianapolis, USA, 2Washington University, Saint Louis, USA

LBP4 - Does the US have enough clinical trials sites to keep up with the demand of new chemical and device compounds entering the NDA?
Sean Stanton1, Dan Davis1, Vishnukarthi Nitta, MS1, Jessica Branning, BS2, John Dwyer, JD3, Jason Borts, MBA3, James Taylor3, and George Vradenburg, JD3
1LifeCore Solutions, LLC, 2ClinCloud, LLC, 3Global Alzheimer’s Platform, 4Bioclinica Research, 5Independent Consultant, Caregiver

LBP5 - Goal Attainment Scaling scores, without defined attainment levels, were associated with standardized measures in people with vascular and mixed dementia
Kenneth Rockwood1,2, Justin Stanley1, Taylor Dunn1, Susan E Howlett1,2
1DGI Clinical Inc., Halifax, NS, Canada, 2Dalhousie University, Halifax, NS Canada

LBP6 - Consultation for Alzheimer’s disease prevention: an effective recruitment strategy for preventive trials
Isabelle Carre, PhD1, Julien Delrieu, MD1,2,3, Françoise Lala, MD1, Christophe Hein, MD1, Delphine Penneiet, PhD1, Pierre Jean Ousset, MD1, Bruno Vellas, MD, PhD2,3
1Gerontopole, Toulouse University Hospital, Toulouse-France, 2Inserm Unit 1027, Toulouse, France, 3University of Toulouse III, Toulouse, France

LBP7 - Finding a common baseline: Insights from latent disease-time progression modeling in Alzheimer’s disease
Lars Lau Rahet1, PhD1
1H. Lundbeck A/S, Denmark

LBP8 - The use of Machine Learning algorithms in Clinical Trials on Alzheimer’s Disease
Delia A. Cheerohge, MSC1, Sarah Bauermeister, PhD1, John Gallacher, PhD1
1University of Oxford, Department of Psychiatry, Oxford, UK

LBP9 - Predicting cerebral amyloid status and cognitive performance in cognitively normal adults
Alette Wessels, PhD1, Adrian Schembri, DPsych2, Pav Kalinowski, PhD1, Reisa Sperling, MD1, Roy Yaari, MD1, Paul Aisen, MD1, David Barfield, MS1, Scott Andersen, MS1, John R. Sims, MD1, A4 Study Team, Paul Maruff, PhD2
1Eli Lilly and Company, Indianapolis, IN, USA, 2Cogstate Ltd, New Haven, Connecticut, CT, USA, 3Center for Alzheimer Research and Treatment, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA, 4Alzheimer’s Therapeutic Research Institute, University of Southern California, San Diego

LBP10 - Novel patient identification and pre-screening model improves patient recruitment and retention and reduces screen-failure rates for AD clinical trials
Laurianne Dobson PhD1, Miguel Rosa Grilo MD1, Catherine Mummery PhD, FRCP1
1Dementia Research Centre, National Hospital for Neurology and Neurosurgery, Queen Square, London, UK

LBP11 - Delivery of a Patient Focused In-Trial Online Community in a Multi-Year Alzheimer’s Disease Study
Adam Butler1, Denis Curtin, PhD1, Machenzie Johnson1, and Jeff Lee1
1CTF, Brachet, Arlington, VA, USA

LBP12 - Multi-crossover randomized controlled trial designs in Alzheimer’s disease
Steven E. Arnold, MD1, Rebecca A. Betensky, PhD1
1Massachusetts General Hospital and Harvard Medical School, Boston, USA, 2Harvard T.H. Chan School of Public Health, Boston, MA
P7 - Effects of vortioxetine on cognitive functions in patients with Alzheimer’s disease and depressive symptoms: interim results of an observational study

Eduardo Cumbo MD1, Silvia Cumbo MD1, Salvatore Torregrossa PsyD1, Daniela Migliore PsyD1
Neurodegenerative Disorders Unit, ASP, Caltanissetta, Caltanissetta (Italy)

P12 - Critical Path for Alzheimer’s Disease (CPAD) consortium’s vision for an aggregated, standardized, and actionable global Alzheimer disease clinical trial database

Volker D. Kern, PhD1, Stephen P. Americ, PhD1, Maria C. Carillo, PhD2, James Hendrix, PhD2, Billy Dunn, MD2, Stacie Weninger, PhD2, Jeffrey A. Kaye, MD1, Daniel R. Karlin, MD2, Lisa H. Gold, PhD2, Michael Gold, MD3, Samantha Budd Haeberlein, PhD4, Molly Shea, PhD5, George Vradenburgll, Daniela J. Conrado, PhD1, and Klaus Romero, MS, MD1
1Critical Path for Alzheimer’s Disease Consortium, Critical Path Institute, Tucson, AZ, USA, 2Alzheimer’s Association, Chicago, IL, USA, 3U.S. Food and Drug Administration, Silver Spring, MD, USA, 4Prime Biomedical Research Initiative, Cambridge, MA, USA, 5Oregon Health & Science University, Portland, OR, USA, 6Pfizer, Boston, MA, USA, 7Merck & Co., Inc., Kenilworth, NJ, USA, 8AbbVie, North Chicago, IL, USA, 9Biogen, Cambridge, MA, USA, 10Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 11UsAgainstAlzheimer’s, Washington, DC, USA

P13 - Effects of body weight on safety of 23mg donepezil in Alzheimer’s disease: A post-hoc analysis of a multicenter, randomized trial

Yun Jeong Hong, MD, PhD1,2, Hyun Jeong Han, MD, PhD3, Young Chul Youn, MD, PhD4, Kyrung Won Park, MD, PhD5, Dong Won Yang, MD, PhD5, Sang Yun Kim, MD, PhD1, Hwa Jung Kim, MD, PhD5, Ji Eun Kim, MD, PhD5, Jee-Hong Lee, MD, PhD5, the ODESA study group
Neurology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, 2Biomedical research institute, Pusan National University Hospital, Pusan, 3Neurology, Dementia and Neurocognitive Center, Myongji Hospital, Seonam University College of Medicine, Ilsan, 4Neurology, Chung-Ang University Hospital, Seoul, 5Neurology, Dong-A University College of Medicine, Busan

P15 - A single ascending dose study to assess the safety, pharmacokinetics, and pharmacodynamics of LY3303560, a tau-specific antibody, in healthy volunteers

Stephen Lowe1, Jeffrey Dage2, Ann Cleverley3, Albert Lo4, Elizabeth S. LaBell5, Hakop Gevorkyan4, Stanford Jhee5, Larry Huffman5, Boris Calderon1, Brian A. Willis2
1Lilly Centre for Clinical Pharmacology, Singapore, 2Eli Lilly and Co, Indianapolis, IN, 3Eli Lilly and Co, Erl Wood, UK, 4California Clinical Trials Medical Group, Inc., 5PAREXEL Early Phase, Glendale, CA, USA

P16 - CNP520, a novel oral BACE1 inhibitor, has no clinically meaningful effect on QTc interval up to supratherapeutic doses

Stefan Vittor Vormfelde, MD/PhD1, Nicole Pezos1, Gilbert Lefèvre, PhD1, Carine Kolly, PhD1, Ulf Neumann, PhD1, Pierre Jordaan, MD2, Guenter Heimann, PhD2, Mike Ufer, MD/PhD1, Ana Graf1, MD2, Eric Legangneux, MD1
Novartis Institutes for BioMedical Research, Basel, Switzerland, 2Novartis Pharma AG, Basel, Switzerland

P18 - Differences in treatment response between males and females with mild-moderate Alzheimer disease being treated with cholinesterase inhibitors

Kenneth Rockwood, MD1,2, Justin Stanley, BSc1, Susan E Howlett, PhD2,3
OGI Clinical Inc, Halifax, NS, Canada, 2Division of Geriatric Medicine, Dalhousie University, Halifax, NS Canada, 3Department of Pharmacology, Dalhousie University, Halifax, NS, Canada

P36 - Phase I Clinical Studies in Alzheimer’s Disease: Cerebrospinal Fluid Oligomer Change and Other Exploratory Outcomes of amyloid β Aggregate-Specific Antibody KHK6640

Marc Cantillon, MD1, Hiroyuki Shimada, MD, PhD2, Kenichiro Sugiyama, Phar.B.3, Wei Sun, Ph.D.4, Yoshiumi Ouchi, M Eng4, Katsuyoshi Tsuhi, MSc1 Gemma Clark, RGN RM6
Kyowa Kirin Pharmaceutical Development, Inc, USA, 2Osaka city university hospital, Osaka, Japan, 3Kyowa Hakko Kirin Co, Ltd, Japan, 4Kyowa Kirin International plc, UK

P80 - Cumulative aducanumab safety data from PRIME: a randomized, double-blind, placebo-controlled, Phase Ib study

Philipp von Rosenstiel MD1, Tianle Chen, PhD1, John O’Gorman, PhD1, Min Yee, PharmD1, Carmen Castillo-Viguera, MD, PhD1, Claudia Prada, MD1, Christoph Hocht, MD1, Roger M Nitsch, MD1, Samantha Budd Haeberlein, PhD1, Alfred Sandrock, MD, PhD1
1Biogen, Cambridge, MA, USA, 2Neurommune, Schlieren-Zurich, and University of Zurich, Switzerland
P109 - The action for health in diabetes clinical trial: does a 10-year intensive multidomain lifestyle intervention provide cognitive benefits?
Kathleen M. Hayden, PhD; José A. Luchsinger, MD; Stephen R. Rapp, PhD; Delilah R. Cook, CCRP; Rebecca H. Neiberg, MS; Judy L. Bahnson, BA; Tara D. Bechler; Jerry M. Barnes, MA; and Mark A. Espeland, PhD for the Look AHEAD MIND Study Group
Wake Forest School of Medicine, Winston-Salem, USA, *Columbia University, New York, USA

P110 - Single and multiple dose safety, tolerability and pharmacokinetics of the selective M1 receptor partial agonist HTLO018318 in healthy volunteers
Tim Tasher MBBS, Jan Liptrot PhD, Charlotte Balther PhD, Ellen ‘t Hart PhD, Erica Klaassen PhD, Samantha Prins MD, Thalia van der Doef PhD, Mike Walter, Giles A. Brown PhD, Alastair Brown PhD, Miles Congreve PhD, Malcolm Weir PhD, Fiona H. Marshall PhD, David M. Cross PhD, Geert Jan Groeneveld MD, PhD, Pradeep J. Nathan PhD, Sosei Heptares, Cambridge UK, *Centre for Human Drug Research (CDHR), Leiden, Netherlands, *Department of Psychiatry, University of Cambridge, UK, *Cross Pharma Consulting Limited, Cambridge, UK

P111 - Assessing the psychological and emotional impact of APOE and amyloid disclosure in the API Generation Program: interim findings
Jessica B. Langbaum, PhD; Jason Karlawish, MD; Scott Roberts, PhD; Angela Bradbury, MD; Scott Kim, MD, PhD; Elisabeth McCarty Wood, MS; Carolyn Langlois, MA; Fonda Liu PharmD, Marie-Emmanuelle Phd, Marie-Laure Rouzade-Dominguez, PhD, Angelita Caputo, PhD, Mauritz Bezuidenhoudt, MSc, Cristina Lopez-Lopez, MD, PhD, Ana Graf, MD, Pierre N. Tariot, MD, Eric M. Reiman, MD
1Banner Alzheimer’s Institute, Phoenix, USA, *University of Pennsylvania, Philadelphia, USA, *University of Michigan, Ann Arbor, USA, *National Institutes of Health, Bethesda, USA, *Novartis Pharmaceuticals Corporation, East Hanover, USA, *Novartis Pharma AG, Basel, Switzerland

P112 - Meta-analysis of two tau aggregation inhibitor Phase 3 trials in mild Alzheimer’s disease with low dose hydromethylthionine
Bjoern Schelter, PhD, Claude Wischik, MD, PhD
*Institute for Complex Systems and Mathematical Biology, University of Aberdeen, Aberdeen, UK, *TauRx Therapeutics, Aberdeen, UK

Late Breaking Posters

LBP13 - Cognitive and mobility training as preventive measures in cognitively healthy patients and patients with MCI
Carine Federpsiel, MD; Elisabeth Bourtel, PhD; Jean-Paul Steinmetz, PhD
*Centre for memory and mobility, ZithaAktiv, Luxembourg, *ZithaSenior, Research&Development, Luxembourg

LBP14 - Evidence of Sustained Low Dose Bryostatin Efficacy for Treatment of Alzheimer’s Disease: Consistency of Multiple Evaluation Analyses
Daniel Alkon, PhD; LJ Wei, PhD; Richard Thompson, PhD
Neuotapex, Inc, *Harvard University, Johns Hopkins University

LBP15 - Enteroviruses might be involved in Alzheimer’s disease - results from a phase IIa trial evaluating Apovir, an antiviral drug combination
Lars-Olof Wahlund, MD, PhD; Lars Lindqvist MD, PhD; Mikael Äström MSc, PhL; Jacob Westman PhD; Roger Bullock MD, PhD; Suzanne Hendrix, Nina Lindblom, PhD

LBP16 - A randomized, placebo controlled, repeat dose phase 1 study of COR388 in older healthy volunteers and patients with Alzheimer’s disease
Samer Kaba, MD; Casey Lynch; Math Ryder, DMD; Ira Goodman, MD; Steve Thien, MD; Steve Dominy, MD

LBP17 - Souvenaid in cognitive deterioration. Our experience after 5 years of treatment and follow-up
Miquel Aguilar MD, PhD and Paquita Soler. Nurse
Àptima Mutua Terrassa, Catalunya, SPAIN
LBP18 - Is RAGE the missing link between diabetes and dementia? Results from a subgroup analysis of the STEADFAST trial

Carmen Valcarce, PhD1, Imogene Dunn, PhD1, Tom Soeder, MS2, and Aaron Burstein, PharmD1

1Vtv Therapeutics LLC, High Point, NC, USA, 2CATO Research Ltd, Durham, NC, USA

LBP19 - Aducanumab 48-month analyses from PRIME, a Phase Ib study in patients with early Alzheimer’s disease

Philipp von Rosenstiel, MD1, Samantha Budd Haebelerin, PhD1, Carmen Castrillo-Viguera, MD1, Tianle Chen, PhD2, John O’Gorman, PhD1, Raj Rajagovindan, PhD1, Datshaben Patel, PhD1, Guanfang Wang, PhD2, Spyros Chaltitas, MD1, LeAnne Stordos PharmD1, Claudia Prada, MD1, Christoph Hoch, MD2, Roger M Nitsch, MD2, Alfred Sandrock, MD, PhD2

1Biogen, Cambridge, MA, USA; 2Biogen, Maidenhead, UK; 3Cytel, Cambridge, MA, USA; 4Neurimmune, Schlieren-Zurich, and University of Zurich, Switzerland

LBP21 - Baseline Data from the API Autosomal Dominant Alzheimer’s Disease Colombia Trial

Pierre N. Tariot1*, Francisco Lopera1*, Kayce M. Sintz1, Nan Hu2, Heather Guthrie3, Jillian Smith4, William Cho5, Jessica B. Langbaum1, Ronald G. Thomas1, Kewei Chen1, Yi Sui1, Dhruman Goradia2, Pradeep Thiyagarajan, Paul S VanGilder1, Ji Luo1, Valentina Ghisays1, Wendy Lee1, Michael H. Malek-Ahmadi1, Hillary D. Protas1, Yinghua Chen1, Carole Ho1, Shehnaz Suliman1, Sergio Alvarez2, Yakeel T. Quiroz3, Robert Paul4, Silvia Rios Romenet5**, Eric M. Reiman**, and the ADAD Colombia Trial Group

1Banner Alzheimer’s Institute, Phoenix, AZ, USA; 2Grupo de Neurociencias de Antioquia of Universidad de Antioquia, Medellin, CO; 3Genentech Inc., South San Francisco, CA, USA; 4Roche Products Ltd, Welwyn Garden City, UK; 5University of California, San Diego, CA, USA; 6Hospital Pablo Tobon Uribe, Medellin, CO; 7Harvard Medical School and Massachusetts General Hospital, Boston MA, USA
Theme 3. Clinical trials: Imaging

P10 - Diagnostic accuracy of [18F]FCI195 PET for identifying Alzheimer’s disease
Byung Hyun Byun, MD, PhD1, Sang Moo Lim, MD, PhD1
1Department of Nuclear Medicine, Korea Cancer Center Hospital, Korea Institute of Radiological & Medical Sciences, Seoul, Republic of Korea

P35 - Annual atrophy rate in normal aging from a large single-center cohort in Korea
Yu Yong Choi1, Byeong C. Kim1, Seong-Min Choi1, Kee Hyung Park2, Kyu Yeong Choi1, Kun Ho Lee1
1National Research Center for Dementia, Chosun University, Gwangju, South Korea, 2Department of Neurology, Chonnam National University Hospital, Gwangju, South Korea

P62 - Impact of cerebral blood flow changes on 18F-florbetaben SUVR. A simulation study
Santiago Bullich, PhD1, Norman Koglin, PhD2, Susan De Santi, PhD3, Georg A. Becher, PhD4, Audrey Perrotin, PhD5, Alexsander Jovalethic, PhD6, Andrew Stephens, MD, PhD1, Henriyt Barhel, MD, PhD7, Osama Sabri, MD, PhD7
1Piramal Imaging GmbH, Berlin, Germany, 2Piramal Pharma Inc., Boston, MA, USA, 3Department of Nuclear Medicine, University Hospital Leipzig, Leipzig, Germany

P76 - F-AV-1451 in TDP-43 associated frontotemporal dementia
Ruben Smith, MD, PhD1, Alexander F Santillo, MD, PhD1, Maria Landqvis Waido, MD, PhD2, Oskar Hansson, MD, PhD3
Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Lund, Sweden, 2Memory Clinic, Angelholm Hospital, Angelholm, Sweden, 3Memory Clinic, Ståde University Hospital, Malmö, Sweden

P113 - Predicting amyloid burden from cognitive assessment
Donald R. Royall, MD1,4, Raymond F. Palmer, PhD4 for the Alzheimer’s Disease Neuroimaging Initiative
Department of Psychiatry, The University of Texas Health Science Center at San Antonio (UTHSCSA), San Antonio, Texas, USA, 2Department of Medicine, UTHSCSA, San Antonio, Texas, USA, 3Department of Family & Community Medicine, UTHSCSA, San Antonio, Texas, USA, 4South Texas Veterans Health Administration Geriatric Research Education and Clinical Center (GRECC), San Antonio, Texas, USA

P114 - The triple use of amyloid PET in Alzheimer’s disease
Michela Rampini, MS3, Moira Marizzoni, PhD1,2, Valentina Garibotto, MD1, Michela Pievani, MD1, Giovanni B Frisoni, MD13
IRCCS Fatebenefratelli, Brescia, Italy, 2Bioclinica, Newark, CA, USA, 3Bioclinica, Philadelphia, PA, USA

P115 - A comparison of cortical reporter regions for longitudinal analysis of 18F-AV1451 PET data
David Scott, PhD1, Katarzyna Adamczut, PhD1, Beth Gorman, BS CNMT2, Maureen Runhle, BS CNMT R.T.(N)3, Joyce Suhy, PhD1 and the Alzheimer’s Disease Neuroimaging Initiative
1Bioclinica, Newark, CA, USA, 2Bioclinica, Philadelphia, PA, USA

P116 - Can tau PET imaging be instrumental in predicting an elevated amyloid level in clinical trials?
Sergey Scherbining, MD1,2, Michael J. Pontecorvo, PhD3, Ming Lu, MD, MS, MPH4, Michael D. Devous Sr, PhD5, A. Joshi, PhD5, Sudeepi Southehal, PhD2, Emily C. Collins, PhD2, Adam S. Fleisher, MD5, Mark A. Mintun, MD2,5
El Lilly & Co, Indianapolis, IN, USA, 2Avid Radiopharmaceuticals, Inc., Philadelphia, PA, USA

P117 - Supratentorial white matter is a better reference for longitudinal quantification of [18F]Flutemetamol scans
Gemma Salvadó MSc1,2, Chris Foley PhD1, Elisabetta Grecchi, PhD2,3, M. Jorge Cardoso, PhD3,4, Isadora Lopes-Alves, PhD4, Pawel Martlewicz, PhD5, Carles Falcom, PhD6, Marth Battle MSc2, Adriaan A. Lammersma, PhD2, Mark Schmidt, MD, PhD7, José Luis Molinuevo MD PhD1, Frederit Barkthof, MD, PhD7,8, Juan Domingo Gispert, PhD9
1IRCCS Fatebenefratelli, Brescia, Italy, 2GE Healthcare, Amersham, United Kingdom, 3IXICO, London, United Kingdom, 4King’s College London, London, United Kingdom, 5University College London, London, United Kingdom, 6VU Medical Center, Amsterdam, The Netherlands, 7Janssen Pharmaceutica, Beerse, Belgium

P118 - Clinical validation of 18F-PI-2620 for quantification of tau in subjects with Alzheimer’s disease
Andrew Stephens1, Andre Mueller1, Santiago Bullich1, Mathias Berndt1, John Seibyl1, Olivier Barret2, Jennifer Madonia2, Heiko Kroth1, Andrea Pfeifer2, Andreas Muh1, Gilles Tamagnan2, Kenneth Mareh1, Ludger Dinkelborg1
1Piramal Imaging, Berlin, Germany, 2InVivo, Neu Haven, USA, 3AC Immune SA, Lausanne, Switzerland

P119 - Cut-off for 18F-Flutemetamol SUVR with white matter reference region
Katarzyna Adamczut, PhD1, David Scott, PhD1, Ben Newton, PhD2, Joyce Suhy, PhD2, Michael Egan, MD2, Cyrille Sur, PhD2
1Bioclinica, Newark, CA, USA, 2Avid Radiopharmaceuticals, Inc., Philadelphia, PA, USA

P120 - Amyloid PET Imaging in a Phase IIa, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Parallel-Group, Multicenter Study with UB-311
Hui Jing Yu1, Hui-Chen Chen1, Jacob Hesterman2, Jack Heimann2, Sean Holmes2, Alex Whittington2, Xue Wang2, Roger Gunn2, Ajay Verma1
1United Neuroscience, Inc. Hauppauge, NY, USA, 2InVivo, A Konica Minolta Company, Boston, MA, USA
CTAD 2018

POSTERS PRESENTATION

P121 - Cortical dopamine depletion and cognition in Lewy bodies disorders: a 123I-FP-CIT single-subject study
Andrea Pilotto1,2 and Francesca Schiano di Cola1, MD and, MD; Enrico Premi1, MD; Roberto Grassol PsyD, Rosanna Turron1, PsyD; MD; Stefano Gippion1, MD; Andrea Scalvini1, MD; Elisabetta Cottini1, Barbara Paghera1, Laura Bonann1, PhD; MD; Maria Cristina Rizzetti1, PhD; Barbara Roni1, MD, Alessandro Padovani1, PhD, MD
Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy; Parkinson's Disease Rehabilitation Centre, FERB ONLUS S. Isidoro Hospital, Trescore Balneario (BG), Italy; Nuclear Medicine Unit, University of Brescia, Brescia, Italy; Department of Neuroscience Imaging and Clinical Sciences, University G. d'Annunzio of Chieti-Pescara, Chieti, Italy.

P122 - Very early detection and treatment monitoring of Alzheimer’s Disease in the retina by multimode, hyperspectral confocal scanning ophthalmoscopy
Daniel L. Farkas, PhD1,2, Fartash Vasefi, PhD1, Jeanne M. Fontana, MD, PhD1
1The Brain Window, Inc., Sherman Oaks CA, USA; 2University of Southern California, Los Angeles CA, USA

P123 - Quantitative Analysis on The Goodness of Harmonization with Multivariate Analysis of Field Strength, Sex, Age and Total Intracranial Volume
Mirza Faisal Beg, PhD, Da Ma, PhD, Karteek Popori, Mahadev, MD1, Lei Wang, PhD1
School of Engineering Science, Simon Fraser University, Vancouver, BC, Canada; Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada; Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA

P124 - Prescribing Cholinesterase inhibitors in mild cognitive impairment – observations from the Alzheimer’s Disease Neuroimaging Initiative
Eddie Stage1, Diana Svadl PhD1, Sophie Soltolow PhD MParm3,5,6, Shannon L. Risacher PhD,1, Krisztina Marosi2, Kwangsik Nho PhD, Jerome I Rotter MD2,3, Andrew J. Saykin PsyD1, Liana G. Apostolova MD MS1
1Indiana Alzheimer Disease Center, Indianapolis, IN, USA; 2UCLA School of Nursing Los Angeles, CA, USA; 3Division of Geriatric Outcomes, Department of Pediatrics and Medicine, Harbor-UCLA Medical Center, Torrance, CA, USA; 4Institute for Translational Genomics and Population Sciences and Department of Pediatrics, Los Angeles Biomedical Research Institute, Torrance, CA, USA; 5UCLA Brain Research Institute, Los Angeles, CA, USA; 6UCLA Clinical and Translational Science Institute, Los Angeles, CA, USA

Late Breaking Posters

LBP21 - Prediction of Treatment Response to Donepezil using Automated Hippocampal Subfields Volumes Segmentation in Patients with Mild Alzheimer’s Disease
Sheng-Min Wang, MD, PhD1, Yoo Hyun Um, MD, PhD1, Chang-Uk Lee MD, PhD1, and Hyun Kook Lim, MD, PhD1
1Department of Psychiatry, Yonsei St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea; 2Department of Psychiatry, St. Vincent’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea; 3Department of Psychiatry, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea

LBP22 - Role of Confluent White Matter Lesions in the progression to Alzheimer’s dementia in an Asian Clinic Cohort
Nagaendran Kandiah
National Neuroscience Institute, Singapore

LBP23 - APOE4/4 Early to Mild AD Subjects Show High Rates of Hippocampal Atrophy and Cognitive Decline in ADNI-I and Tramiprosate Datasets
Susan Abushakra MD1, Luc Bracoud MSc, Joel Schayer2, Aidan Power MD1, John Hey Phd1, David Scott PhD1, Joyce Suhy PhD1, Martin Tolar MD PhD1 & the Alzheimer Disease Neuroimaging Initiative (ADNI)
1Alzheon Inc, Framingham, MA, USA; 2Bioclinica, Lyon France; 3Bioclinica, Newark CA, USA

LBP24 - Preliminary characterization of 18F-RO948 PET imaging among cognitively unimpaired and patients with MCI or dementia in the BioFINDER2 study
Gregory Klein1, Ruben Smith1, Sebastian Palmqvist1, Niklas Mattsson2, Daniëlle van Westen1, Olof Strandberg2, Jonas Jögi3, Tomas Ohlsson1, Edilio Borron1, Preciosa Coloma1, Eirik Stromrud2, Oskar Hansson3
1Roche Pharma Research and Early Development, Basel, Switzerland; 2Clinical Memory Research Unit, Lund University, Sweden

CTAD 2018 - 29
P1 - Sustained attention and memory tasks with concurrent EEG provide potential biomarkers for mild cognitive impairment
Shani Waniegold, Ph.D.,1 Chris Berhal, Amir Meghdadi, Ph.D.,1 David Salat, M.D.2 and Ajay Verma, M.D., Ph.D.3
1Advanced Brain Monitoring, Inc., Canandaigua, NY. 2MGH/MBI/HMS Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Charlestown, MA. 3United Neuroscience, Dublin, Ireland

P4 - High correlation in the Aβ40 and Aβ42 levels in human cerebrospinal fluid as measured by ELISA and HPLC-MS/MS
Jose A. Alfue, PhD, Leticia Sarasa, PhD, Virginia Pérez-Grijalba, PhD, Noelia Fandos, PhD, Pedro Pesini, PhD, Manuel Sarasa, PhD.
Accion Biotech S.L., Via Hispalidad 21, 50.009, Zaragoza, Spain

P22 - Cerebrospinal fluid biomarkers in J-ADNI: diagnostic accuracy in AD and predictability of future clinical change in MCI
Kazushi Suzuki MD, PhD1, Ryoto Iha MD, PhD, Atsushi Isawa MD, PhD2, Takeshi Isawaburo MD, PhD1, Kenji Ishii MD1, Takeshi Itoichi MD, PhD1, Ryozo Kuwano MD, PhD1, Japanese Alzheimer's Disease Neuroimaging Initiative
1The University of Tokyo, Tokyo, Japan. 2Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan. 3Nagita University, Nagita, Japan

P28 - Analytical performance of the Lumipulse® G pTau 181 and Lumipulse® G β-Amyloid 1-40 assays
Manu Vandijk, Martine Dauwe, Rosina Degrieck, Eis Huych, Nathalie Le Basard, Geert Jansen, Vesas Kostanjevce
Pujirejio Eurove Nv, Chent, Belgium

P30 - Curcumin is Detectable in Human Cerebrospinal Fluid after Oral Administration of Turmeric Extract HSRx-888
Norman Relkin MD, PhD, Dan Li PhD2, Joshua Costin PhD, David Wyatt MD1
1Reithin Consulting LLC, Hanovering Park, NJ 07640, USA. 2HeraldScience Group, Naples FL, USA. 3Syneos Health, Miami, FL, USA

P39 - Diagnostic biomarkers’ clinical applicability in early onset Alzheimer’s disease
Neus Falgàs, Raquel Sánchez-Vallé1, Mircea Balasa1, Sergi Borrego1, Magdalena Castellví1, Adrià Tort Merino1, Jaume Olives1, Beatriz Bosch1, Guadalupe Fernández1, Francisco Lomeña2, Núria Bargalló1, Albert Liadò3
1Alzheimer's disease and other cognitive disorders Unit. IDIBAPS. Hospital Clinic de Barcelona, 2Atlantic Fellow for Equity in Brain Health. Global Brain Health Institute. Trinity College Dublin, Ireland, 3Image Diagnostic Centre. IDIBAPS. Hospital Clinic de Barcelona

P44 - Inverse association between Aβ42/40 plasma ratios and fibrillary amyloid deposition in the brain: results of the FACEHBI study
Izziar de Rojas, MSC1, Judith Romero, MSC2, Octavio Rodriguez-Gomez, MD, Pedro Pesini, PhD1, Angela Sanabria, PhD1, Alba Pérez Cordon, MSC1, Carla Abeldeanu, MD, PhD1, Isabel Hernandez, MD, PhD1, Maite Rosende-Roca, MD, Ana Mauleon, MD1, Liliana Vargas, MD1, Montserrat Algeret, Ph.D1, Ana Espinosa, Ph.D1, Gemma Ortega, PhD1, Silvia Gi1, MD, PhD1, Marina Guitant, MSC1, Anna Gallhajenat, MSC1, Miguel Angel Santos Santos, MD, PhD1, Sonia Moreno Grau, MSC1, Oscar Sotolongo Grau, PhD, Susana Ruiz, MN, Laura Montreal, MLT1, Elvira Martin, MSC1, Esther Peléja, Francisco Lomeña, MD, PhD1, Francisco Campos, PhD1, Assumpita Vivas, MD1, Marta Gómez Chiari, MD1, Miguel Angel Tejero, MSC1, Joan Gámínez, MD1, Virginia Pérez Grijalba, MD, Marta Marqué, MD, PhD1, Gemma Monté Rubio, PhD1, Sergi Valero, PhD1, Adelina Orellana, PhD1, Lluis Tarraga, MSC1, Manuel Sarasa, PhD2, Agustin Ruiz, MD, PhD1, Mercè Boada, MD, PhD3, on behalf of the FACEHBI study
1Research Center and Memory Clinic. Fundació ACE. Institut Català de Neurociències Aplicades, UIC-Barcelona, Spain, 2Atlantic Fellow for Equity in Brain Health. Global Brain Health Institute. Trinity College Dublin, Ireland, 3Department de Diagnòstic per la Image. Clínica Coral, Barcelona, Spain

P57 - Concordance of the CSF Abeta42/Abeta40 ratio with amyloid-PET in the BioFINDER study
Oskar Hansson MD PhD1,2, Katharina Zinl MSC1, Simone Wahl PhD1, Moniha Widmann ChTech1, Sandra Rutz PhD1, Maryline Simon PhD5, Kaj Blennow MD PhD1,2, Erif Stornrad MD PhD1
1Clinical Memory Research Unit, Lund University, Malmö, Sweden. 2Memory Clinic, Södertörn University Hospital, Malmö, Sweden. 3Memory Clinic, Strönne University Hospital, Malmø, Sweden. 4Centralised & Point of Care Solutions, Roche Diagnostics GmbH, Penzberg, Germany. 5Centralised & Point of Care Solutions, Roche Diagnostics GmbH Malmö, Sweden. 6Institute of Neuroscience and Physiology, Dept. of Psychiatry and Neurochemistry, The Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden

P64 - Novel pre-analytical protocol for handling of cerebrospinal fluid samples for the analysis of Alzheimer’s Disease biomarkers in clinical practice
Oskar Hansson MD PhD1,2, Erif Stornrad MD PhD1,2, Sandra Rutz PhD1, Valeria Lifie PhD1, Elfraterina Bauer MBA PhD1, Udo Eichenbaum PhD1, Richard Batia PhD1, Elfraterina Manuivola MSC,b, Mehmet Can Mert PhD1, Simone Wahl PhD1, Kaj Blennow, MD, PhD1,6, Erif Stornrad MD PhD1
1Clinical Memory Research Unit, Lund University, Malmö, Sweden. 2Memory Clinic, Södertörn University Hospital, Malmø, Sweden. 3Centralised & Point of Care Solutions, Roche Diagnostics GmbH, Penzberg, Germany. 4Centralised & Point of Care Solutions, Roche Diagnostics International, Rathide, Switzerland. 5Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden. 6Institute of Neuroscience and Physiology, Dept. of Psychiatry and Neurochemistry, The Sahlgrenska Academy at University of Gothenburg, Mölndal, Sweden
P65 - Serum-Based Proteins as Novel Biomarkers for the Diagnosis of Alzheimer’s Disease
Shuyu1, Yue-Ping Liu2
1State Key Laboratory of Military Stomatolgy and National Clinical Research Center for Oral Disease and Shaanxi Clinical Research Center for Oral Disease, Department of Laboratory Medicine, School of Stomatolgy, Fourth Military Medical University, Xi’an, Shaanxi Province 710000, China. 2Department of Laboratory Medicine, 477th Hospital of PLA, Xiangyang, Hubei Province 400013, China. *Corresponding author

P66 - TREM2 DNA methylation: A potential biomarker or therapeutic target
Lynn Behris1, Rumana Ahhter1, Yvonne Sha1, Maria Khrestian1, Giana D’Aleot1, Shane Formica1, James B. Leverenz2
1Genomic Medicine Institute, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, 2Cleveland Clinic Lou Ruvo Center for Brain Health, Cleveland Clinic, Cleveland, Ohio

P73 - Immune state in cognitive impairment of aged and the use of Actovegin and Ceraxone in out-patients of Alzheimer’s centre
Nataliya Mihaylova1, Lubov Androsova2
1MD, PhD Geriatric psychiatry. Department, Mental health research centre, Moscow, Russia. 2PhD, Immunology laboratory, Mental health research centre, Moscow, Russia

P78 - Modifiable Alzheimer’s risk biomarkers
Christine Ganzel1, Alon Seifan, MD, MD, Krista Ryon1, Elizabeth Maiche MCMsc, PA-C4
1Hunt College, NY, NeuroWell Free, Ft. Lauderdale, Florida, 2Hunt College, NY, NeuroWell Free, Ft. Lauderdale, Florida

P81 - Serum NFL, TAU, GFAP and UCHL-1 in Alzheimer disease patients with different decline profile
Melissa Jacob1,2, Alekseandra Maceschi, PhD1, Sienie Richaert PhD1,2, Audrey Gabelle MD, PhD1,2, Sylvain Lehmann MD, PhD1
1Memory Research and Resources Center, Department of Neurology, Montpellier University Hospital, Montpellier, France, 2Université de Montpellier, MUSE, Montpellier, France, 3Inserm U1183 IRMB, Montpellier, France, 4Inserm U1061, La Colombière Montpellier University Hospital, Montpellier, France

P125 - An ultra-sensitive molecular immuno-assay for quantification of human SNAP25 in cerebrospinal fluid
Eugene Vanmchehen, PhD1, Jeroen Vanbrabant, PhD1, Naomie De Roest, BcS2, Maria Bjerke, PhD2,3, Sebastiaan Engelenborghs, MD, PhD,2,3, Ann De Vos, PhD
1ADx NeuroSciences NV, Ghent, Belgium, 2Reference Center for Biological Markers of Dementia (BIODEM), Institute Born-Bunge, University of Antwerp, Antwerp, Belgium, 3Department of Neurology and Memory Clinic, Hospital Network Antwerp (ZNA) Middelheim and Hoog Beuken, Antwerp, Belgium

P126 - Plasma and CSF biomarkers for the diagnosis of Alzheimer’s disease in adults with Down Syndrome. A cross-sectional study
Maria Carmona-Iragui, MD, PhD1,2, Bessy Benejam, MSc, Susana Fernández, MD, Laura Videla, MSc1,2, Isabel Barroeta, MD, PhD1,2, Daniel Alcolea, MD, PhD1, Jordi Pegueroles, MSc1, Laia Muñoz, MSc1,2, Olivia Belbin, PhD2, Jordi Clarín, MD, PhD1,2, Mony John de Leon, Ed.D2, Sebastián Videla, MD, PhD1,2, Alekseandra Maleša Maceschi, MSc2, Christophe Hirze, PhD2, Constanze Delaby, PhD2, Sylvain Lehmann, PhD2, Rafael Blesa, MD PhD1, Alberto Lleó, MD, PhD1,3, Juan Fortea, MD, PhD1,2,3
1Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau-Biomedical Research Institute Sant Pau-Universitat Autònoma de Barcelona, Spain, 2Barcelona Down Medical Center. Fundació Catalana de Síndrome de Down, Barcelona, Spain, 3Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED), Spain, 4New York University School of Medicine, NYU Center for Brain Health, Department of Psychiatry, New York, USA

P127 - The application of Polygenic Risk Score analysis to Stratification of Subjects for Clinical Trials in Alzheimer’s Disease in carriers and non-carriers of the ApoE4 risk allele
Richard Pitthe1, PhD, Ganna Leonenko, PhD, Rebecca Simms1, Paula Daunt PhD2, Greg Davidson PhD2, Alex Gibson PhD2, Olusegun Oshota PhD1, Maryam Shoai PhD2, Kevin Banths2, Simon M Laws PhD2, Zsuzsanna Nagy2 and John Hardy, PhD, DSc2, Julie Williams PhD2,3, Valentina Escott-Price, PhD2,4
1Cardiff University, Cardiff, United Kingdom, 2Cytox Ltd, UK, Oxford, United Kingdom, 3ULC Institute of Neurology, London, United Kingdom, 4Edith Cowan University, Australia, 5Co-operative Research Centre (CRC) for Mental Health, Perth, Australia, 6University of Birmingham, United Kingdom, 7Dementia Research Institute, Cardiff, United Kingdom

P128 - Do short Aβ peptides impact the time course of cognitive decline? An ADNI analysis
Markus von Kienlin, PhD1, Paul Deim1, PhD, Katharina Buch, PhD2, Charlotte Schärfe1, Simone Wahl, PhD2, Karlheinz Baumann, PhD2, Irene Gerlach, PhD1, Tania Niholchake, MD, PhD2
1Neurodegenerative Diseases Center, Department of Neurology and Memory Clinic, Hospital Network Antwerp (ZNA) Middelheim and Hoog Beuken, Antwerp, Belgium, 2Centre de Recherche en Neurosciences, Université Libre de Bruxelles, Brussels, Belgium

P129 - Measuring oligomerization tendency of plasma as a new blood-based biomarker for Alzheimer’s disease
SangYun Kim, MD, PhD1,2, Sunghim Kang, MS3, Seong Soo A. An, PhD2, Young Chul Youn, MD, PhD3
1Department of Neurology, Seoul National University College of Medicine, 2Clinical Neuroscience Center, Seoul National University Bundang Hospital, 3PeopleBio Company, 4Department of BioNano Technology, Gaon Medical Research Institute, Gaon University, 5Department of Neurology, Chung-Ang University College of Medicine
P130 - Transcranial magnetic stimulation predicts cognitive decline in Alzheimer’s disease patients
Giacomo Koch MD, PhD1, Caterina Motta MD, Francesco Di Lorenzo MD, Maria Concetta Pellicciari PhD, Sonia Bonni PhD, Silvia Picazio PhD, Carlo Caltagirone MD, Alessandro Martorana MD
Department of Behavioral and Clinical Neurology, Sonia Lucia Foundation IRCRS, Rome, Italy; University of Tor Vergata, Rome, Italy.

P131 - Non-core biomarkers (neurofilament light, neurogranin, 14-3-3 and YKL-40) in the Alzheimer’s disease continuum, frontotemporal dementia and prion diseases diagnosis
Anna Antonelli PhD, Adria Tort MSc, José Rios MSc, Sergi Borrego MD, Mircea Balasa MD, Cristina Muñoz-García, Beatriz Bosch PhD, Neus Falgàs MD, Lorena Rami PhD, Kai Blennow MD, PhD, Henrik Zetterberg PhD, José Luis Molinuevo MD, PhD, Albert Lladó MD, PhD, Raquel Sánchez-Valle MD, PhD
Alzheimer’s disease and other cognitive disorders Unit, Hospital Clinic, IDIBAPS, Barcelona, Spain; Medical Statistics Core Facility, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) and Hospital Clinic, Barcelona, Biostatistics Unit, Faculty of Medicine, Universitat Autònoma de Barcelona; Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; Department of Molecular Neuroscience, University College London, London, UK.

P132 - Amyloid blood biomarker detect Alzheimer’s disease
Klaus Gerwert, Prof. Dr.
Ruhr-Universität Bochum, Bochum, Germany.

P133 - Early diagnosis of Mild Cognitive Impairment and Alzheimer’s disease based on salivary lactoferrin
Eva Carro, Gortha Drive
Networked Biomedical Research Center in Neurodegenerative Diseases (CIBERNED), Spain; Group of Neurodegenerative Diseases, Hospital 12 de Octubre Research Institute (imas12), Madrid, Spain; Laboratory of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of the Basque Country, Vitoria, Spain; Networked Biomedical Research Center in Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Spain.

Anna Antonelli PhD, Raquel Sánchez-Valle MD, Neus Falgàs MD, Mircea Balasa MD, PhD, Debyan Datta PhD, Luis Armengol PhD, Sergi Borrego MD, Guadalupe Fernández, Beatriz Bosch PhD, Jaume Olives Cristina Muñoz-García, Maria León, Magdalena Castellví, Adrià Tort, Albert Lladó, MD, PhD
Alzheimer’s disease and other cognitive disorders Unit, Hospital Clinic, IDIBAPS, Barcelona, Spain; qGenomics (Quantitative Genomic Medicine Laboratories), Esplugues de Llobregat, Spain.

P135 - The future of blood-based hinze biomarkers in Alzheimer’s disease
Jacques Hugon, Julien Dumurgier, Emmanuel Cognat, Claire Paquet
Center of Cognitive Neurology, Lariboisière Hospital, AP-HP, University of Paris Diderot, Paris France.

P136 - A prototype SIMOA assay quantifying plasma amyloid beta 1-42 and 1-40 isoforms can differentiate AD from healthy control subjects
Charlotte E. Teunissen PhD, Elisabeth Thijsse MSc, Inge M.W. Verberk MSc, Hugo Marcel Vanderstichele PhD, Hans Heijst, Harry Twaalfhoven, Kimberley Mauroo BSc, Philip Scheitens, MD, PhD, and Erij Stoops, Eng
Neurochemistry Laboratory and Biobank, Amsterdam University Medical Center, Amsterdam, Netherlands; Neurochemistry Laboratory, Department of Clinical Chemistry, Amsterdam Neuroscience, Amsterdam University Medical Center Amsterdam, Netherlands; ADx NeuroSciences, Gent, Belgium; Amsterdam University Medical Center, Department of Neurology, Amsterdam, Netherlands.

P137 - Serum-Based Proteins as Novel Biomarkers for the Diagnosis of Alzheimer’s Disease
Shu Yu*, Yue-Ping Liu
State Key Laboratory of Military Stomatology and National Clinical Research Center for Oral Disease and Shanxi Clinical Research Center for Oral Disease, Department of Laboratory Medicine, School of Stomatology, Fourth Military Medical University, Xi’an, Shaanxi Province China; Department of Laboratory Medicine, 417th Hospital of PLA, Xiangyang, Hubei Province, China. * Corresponding author

P138 - Inflammatory markers tracking cognitive and biomarker heterogeneity in MCI stage of Alzheimer’s Disease
Jagan A Pillai MBBS PhD, James Bena MS, Lynn M Beitris PhD, James B Leverenz MD
Lau Ravo Center for Brain Health; *Neurological Institute and Department of Neurology, *Quantitative Health Sciences, *Ceramic Medicine Institute, Cleveland Clinic, Cleveland, OH, USA.

P139 - The pitfalls for clinical trials of the use of time points earlier than 90 min for the [18F]MK-6240 SUVR calculation
Tharick A. Pascoal MD, Sulantha Mathotaarachchi MSc, Mira Chamoun PhD, Joseph Therriault BSc, Robert Hopewell PhD, Gassan Massarweh PhD, Andrea L. Benedet, MSc, BSc, Min Su Kang, Serge Gauthier, MD, Pedro Rosa-Neto, MD, PhD
Translational Neuroimaging Laboratory, McGill University Research Centre for Studies in Aging, McGill University, Montreal, Canada.
Late Breaking Posters

LBP25 - Discovery of AN Endogenous Metabolite of Tramiprosate and its Prodrug ALZ-801 that Inhibits Beta Amyloid Oligomer Formation in Human Brain
John A. Hey, Pet Kocis, Jatub Horton, Susan Abushatal, Aidan Power, Martin Vynhnalek, Jeremy Y. Yu and Martin Tolar
Alzheimer, Inc, Framingham, MA, USA, 2International Clinical Research Centre, St. Anne's University Hospital Brno, Brno, Czech Republic, 3Cognitive Center, Department of Neurology, Charles University, 2nd Faculty of Medicine and Masol University Hospital, Czech Republic

LBP26 - Novel use of aptamer libraries for prediction of amyloid status from blood serum
Gregory Perry, Sozic Lecocq, Anakiele Chopin, Sima Liskovska, Andrea Vergallo, Enrica Cavedo, Francois-Xavier Lejeune, and Harald Hampel, the INSIGHT-preAD study group and the Alzheimer Precision Medicine Initiative (APMI)

LBP27 - Novel cerebrospinal fluid synaptic markers in Alzheimer’s disease for potential use in clinical trials
Alberio Lioe MD, PhD, Raúl Núñez-Llaves, Daniel Alcolea MD, PhD, Marti Colom-Cadena PhD, Laia Muñoz, Marta Querol-Vilaseca, Jordi Pegueroles, Lorena Ramí PhD, Albert Llado MD, PhD, José L. Molinuevo MD, PhD, Mikel Tainta MD, PhD, Jordi Claramon PhD, Tari Spires-Jones PhD, Rafaela Biesa MD, PhD, Juan Fortea MD, PhD, Pablo Martinez-Lage MD, PhD, Raquel Sanchez-Valle MD, PhD, Alex Bayés PhD, Olivia Bebin PhD

LBP28 - Diminished platelet-derived hsa-miR-150-5p expression as biomarker for dementia with Lewy bodies versus Alzheimer's disease
Katrin Beyer, PhD, Ana Gámez-Valero, PhD, Jaume Campbellacre, MD, PhD, Dolores Vilas, MD, PhD, Lourdes Ispierto, MD, PhD, Jordi Gascon-Bayami, MD, Ramon Reher, MD, PhD, Ramiro Alvarez, MD, Maria A. Amengol, PhD, Francis E. Borrias, PhD

LBP29 - Development of polygenic risk scores (PRS) for common neuropathology
Julie Collens, PhD, Mitte Nalls, PhD, Marcel van der Brug, PhD

LBP30 - The Italian Inter-Societal consensual algorithm for the biomarker-based diagnosis of mild cognitive impairment
Marina Boccardi, PhD, Valentina Nicolosi, MS, Cristina Festari, MS, Angelo Bianchetti, MD, Stefano Cappa, MD, Davide Chiasserini, PhD, Andrea Falini, MD, Ugo Paolo Guerra, MD, Flavio Nobili, MD, Alessandro Padovani, MD, Giulia Maria Sanseverino, PhD, Francesca Benedetta Pizzini, PhD, Alberto Beltrame, MD, Marcello Ciaccio, M.D., Orazio Schillaci, M.D., Marco Trabucchi, M.D., Fabrizio Tagliavini, MD, Giovanni Batista Frisoni, MD

LBP31 - Secondary structure of Aβ as blood biomarker
Klaus Gerwert, Department of Biophysics Ruhr University Bochum, Germany
LBP32 - BDNF as a biomarker for the effects of p38 MAPKα inhibition on IL-1β-induced impairment of hippocampal synaptic plasticity
John Alam MD, Charlotte Teunissen PhD, Niels Prins MD PhD, Hui-May Chu PhD, Philip Scheltens MD PhD
EIP Pharma Inc, Cambridge MA, USA, 2Department of Clinical Chemistry, VU University Medical Center, Amsterdam, NL, 3Department of Neurology and Alzheimer Centre, VU University Medical Center, Amsterdam, NL, 4Brain Research Center, Amsterdam, NL, 5Anoixis Corporation, Framingham MA, USA

LBP33 - Impact of pre-analytical sample handling on Elecsys Aβ40, Aβ42 and tTau immunoassays in plasma
Malgorzata Rozga, PhD, Tobias Bitma, PhD, Richard Bartla-Utermann, MD, MBA, Johann Karl, PhD
Roche Diagnostics GmbH, Penzberg, Germany, 2Genentech, a member of the Roche Group, Basel, Switzerland, 3Roche Diagnostics International AG, Rotkreuz, Switzerland

LBP34 - Agreement between visual amyloid PET and cerebrospinal fluid Aβ1-42, Aβ1-40, t-Tau and p-Tau on the LUMIPULSE G fully automated platform
Alberto Llo1, Jordi Pegueroles1, Laia Muñoz1,2, Valé Camacho1, Diego López-Mora1, Alejandro Fernández-León1, Nathalie Le Bastard1, Ehsan Huyect, Alicia Nadal1, Verónica Olmedo1, Victor Montal1,2, Eduard Vilaplana1,2, Rafael Blesa1,2, Juan Fortea1,2, Daniel Alcolea1,2
1Sant Pau Memory Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, University Autónoma of Barcelona, Barcelona, Spain, 2Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas, CIBERNED, Spain, 3Nuclear Medicine Department, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, University Autónoma of Barcelona, Barcelona, Spain, 4Fujirebio Europe NV, Cens, Belgium, 5Fujirebio Iberia, SLU, Barcelona, Spain

LBP35 - Does non-disclosure of APOE genotyping prevent subject interest or participation in clinical trials?
Sean Stanton1, Vishnuvrat Nitta, MS2, Jessica Branning, BS2
1LifeCore Solutions, Winter Park, USA, 2ClinCloud, LLC, Orlando, USA

LBP36 - Measurement of pathological amyloid in a patient cohort in routine clinical assessment: comparison of visual [18F]Flutemetamol PET read and CSF measures
Nenad Bogdanovic1, Enrico Fantoni2 & Gill Farrar2
1Karolinska Institutet, Stockholm, Sweden and University Hospital Oslo, Oslo University, Norway, 2GE Healthcare Life Sciences, Amersham, UK and Boston, USA

LBP37 - Kinetic measurement of newly generated BACE1-cleaved APP in the human central nervous system in Alzheimer’s disease: a pilot study
Robert J. Vassar, PhD, Randall J. Bateman, MD, Bruce W. Patterson, PhD, Justyna A. Dobrowolska Zaharia, PhD
Department of Neurology, Northwestern University, Feinberg School of Medicine, Chicago, IL, USA, 2Department of Neurology, Washington University in St. Louis, St. Louis, MO, USA, 3Department of Medicine, Washington University in St. Louis, St. Louis, MO, USA

LBP38 - Reliability of a rapid APOE assay for Alzheimer’s risk assessment and clinical trial screening
Athena Lee, PhD, William Menard, BA, Gina Tonini, MBA, Louise Thompson, PhD, Jessica Alber, PhD, Stephen Salloway, MD
Warren Alpert Medical School of Brown University, Providence, RI, USA, 2Butler Hospital, Providence, RI, USA

LBP39 - Cerebrospinal fluid profiling of multiple pathophysiological pathways in Alzheimer’s disease
Steven Arnold MD, PhD, Bianca A. Trombetta, Becst C. Carlyle, PhD
Massachusetts General Hospital and Harvard Medical School, 1Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA

LBP40 - Interim biomarker analyses of phase II study data on safety and efficacy of GMCSF in mild-to-moderate Alzheimer’s disease
Timothy D. Boyd, PhD, Jonathan Woodcock, MD, Stefan Silla, PhD, Vanessa Adame, BS, Thomas Borges, MD, Ashesh Thaker, MD, Brianne Betcher, PhD, Joseph Daniels, MS, Kate Heffernan, BS, Huntington Potter, PhD
Rocky Mountain Alzheimer’s Disease Center, University of Colorado Anschutz Medical Campus, Aurora, CO, USA, 2Linda Cmn Institute for Down Syndrome, University of Colorado Anschutz Medical Campus, Aurora, CO, USA, 3Department of Neurology, University of Colorado at Anschutz Medical Campus, Aurora, CO, USA, 4Department of Radiology, University of Colorado at Anschutz Medical Campus, Aurora, CO, USA, 5Department of Neurosurgery, University of Colorado at Anschutz Medical Campus, Aurora, CO, USA
**Theme 5. Clinical trials: Cognitive and functional endpoints**

**P2 - Objectively measured physical activity and cognitive function**
Hiroyuki Umegaki1, Taeko Makino2, Kazuki Uemura3, Hiroyuki Shimada4, Xian Wu Cheng5

1MD, PhD, Department of Community Healthcare & Geriatrics, Nagoya University Graduate School of Medicine, Aichi, Japan, 2PhD, Institute of Innovation for Future Society, Nagoya University, Aichi, Japan, 3Liberal Arts and Sciences, Faculty of Engineering, Toyama Prefectural University, Toyama, Japan, 4Department of Preventive Gerontology, Center for Gerontology and Social Science, National Center for Geriatrics and Gerontology, Obu, Japan, 5MD, PhD, Institute of Innovation for Future Society, Nagoya University, Aichi, Japan

**P3 - D-Cycloserine improves difficult discriminations in a pattern separation task in Alzheimer’s disease: Implications for dentate gyrus activity and neurogenesis**
Pascal J. D. Goetghebeur1, Keith A. Wesnes2, Steven D. Targum3

1Bracket LLC, Reading, UK, 2Wesnes Cognition Ltd, Streatley on Thames, UK, 3Bracket LLC, Boston, US

**P8 - A Multicenter, Open-label, 24-week Follow-up Study for Efficacy on Cognitive Function of Donepezil inBinswanger-Type Subcortical Vascular Dementia**
Jay Cheol Kwon4, Eung Gyu Kim, M.D.5, Jae Woo Kim, M.D.6, Oh Dae Kwon, M.D.7, Bong Goo Yoo M.D.8, Nam-Gon Kim, M.D.9, Nack Cheon Choi, M.D.10, Seong young Ahn, M.A.11, Byung Hwa Lee, M.D.12, Myong Jin Kang, M.D.13, Dae Seob Choi, M.D.14, The BKVD Study Group

4Department of Neurology, Changuaen Fatima Hospital, Changuwon, Korea, 5Samsung Changuwon Hospital, Changuwon, Korea, 6The Republic of, 7SAMSUNG CHANGWON HOSPITAL, CHANGWON, KOREA, 8The Republic of, 9Changwon Fatima Hospital, Changuwon, Korea, 10The Republic of, 11Changwon Fatima Hospital, Changuwon, Korea, 12Samsung Changuwon Hospital, Changuwon, Korea, 13The Republic of, 14Changwon Fatima Hospital, Changuwon, Korea

**P9 - The Correlation of Diabetic Status, Ischemic and Atrophic Burdens on Brain MRI and Cognitive Decline inSeventh Decade Diabetic Patients with Cognitive Impairment. -1 Year Prospective, Observational Study**
Jay Cheol Kwon4, Kyungsoo Lee, MD, Yohan Jung, MD, PhD, Sungrae Cho, MD, PhD, And Nack-cheon Choi, MD, PhD.

4Department of Neurology, Changuwon Fatima Hospital, Changuwon, Korea, 5Samsung Changuwon Hospital, Changuwon, Korea, 6The Republic of, 7Kyeongsang National University Hospital, Chirung, Korea, 8The Republic of

**P19 - Lanabecestat: Central monitoring of rater performance and error characteristics of efficacy assessments in the AMARANTH study**
Alette M. Wessels1, Lisle R. Kingery2, Edward I. Bartolic2, Laura E. Nichelli, Jamie A. Mullen5, John R. Sims1

1Eli Lilly and Company, Indianapolis, IN, USA, 2Cogstate, New Haven, USA, 3AstraZeneca Pharmaceuticals, Cambridge, MA, USA

**P25 - Effects of sex, educational background, and CKD grading on cognitive and functional decline in JapaneseADNI study**
Atsushi Iwata1, Ryoho Ihara1, Kazushi Suzuki, MD1, Takeshi Iwarsubo, MD1, and the Japanese ADNI1

1Department of Neurology, The University of Tokyo Hospital, Tokyo, Japan, 2Unit for Early and Exploratory Clinical Development, The University of Tokyo Hospital, Tokyo, Japan

**P26 - A German version of the “Five Word Test” – Discriminating patients with mild cognitive impairment/mildAlzheimer’s disease, healthy controls and patients with depression**
Hausner L, MD, Dinu-Bringer R, PhD, Frölich L, MD, PhD

Department of Geriatric Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Germany

**P27 - Use of Medications on Transcranial Doppler Vasoreactivity in Mild Cognitive Impairment**
Shim YongSoo, Jung San

Department of Neurology, College of Medicine, The Catholic University of Korea, Seoul, Korea, Department of Neurology, Hallym University Medical Center, Kang Nam Sacred Heart Hospital, Seoul, Korea, Department of Neurology, Bucheon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Republic of Korea

**P53 - MMSE screening data quality for Alzheimer’s disease studies across countries**
Jordan Mark Barbone, BA, Todd M. Solomon, PhD1, H. Todd Feaster, PsyD1, Macarena Garcia-Valdecasas Colell, MSc2, & David S. Miller, MD, MA1

1Brachet, Wayne, PA, USA, 2Boston University School of Medicine, Boston, MA, USA, 3Brachet, Reading, UK

**P67 - The presence of identical scoring on the MMSE and ADCS-ADL in Alzheimer’s disease clinical trials usingenhanced eCOA devices**

1Brachet, Wayne, PA, USA, 2Boston University School of Medicine, Boston, MA, USA
P69 - Neuroplasticity-based visual alertness training and improvements in declining executive functions in healthy older adults
Thomas Van Vleet, PhD1, Joseph DeGutis, PhD2,3, Michelle Voss, PhD4
Research and Development, Pposit, Science, San Francisco, CA, USA, 1School of Medicine, Harvard University, Boston, MA, USA, 2Boston VA, Boston, MA, USA, 3Psychology Department, University of Iowa, Iowa City, IA, USA

P71 - The treatment response of Goal Attainment Scaling in relation to goal number in a clinical trial of Alzheimer’s Disease Patients
Kenneth Rockwood, MD1,2, Lisa McGarrigle, PhD1,2
Division of Geriatric Medicine, Dalhousie University, Halifax, NS, Canada, 1DGI Clinical Inc., Halifax, NS, Canada

P74 - Predictive value and test-retest reliability of the tablet-based Brief Assessment of Cognition (BAC App) for assessment of cognition in aging: preliminary findings from an ongoing normative study
Anzalee Khan PhD1,2, Danny Ulshen BA1, Alexandra Athing PhD1, Daniela Balientin BA1, Adam Vaughan PhD1, Heather Dickerson PhD1, Brenda L. Plassman PhD1, Kathleen A. Welsh-Bohmer PhD1, Rich Keefe PhD1,2
NeuroCog Trials, Durham, NC, USA, 1Nathan S. Kline Institute for Psychiatric Research, Orangeburg, NY, USA, 2Duke University, Durham, NC, USA

P77 - Clinical and Amyloid Screen Failure Rates in Episodic Memory Measures of Early AD Trials
Selam Negash1, Christopher Weber1, Christopher Randolph1
MedAvante-ProPhase, 1Loyola University Medical Center

P83 - Determinants of care refusal: from patients suffering from dementia to their caregivers characteristics’
Gaëstel, Y. Phd, CERDA S, MD
Memory Center, Bagatelle Hospital, Toulouse, France

P140 - Item bias in the measurement of functional impairment: a cross-cultural comparability study in eight international cognitive aging studies
Siechtke A. M. Sibthorpe, PhD1,2, Marit A. Dubbelman, MSc1, Merite Vertijiri, MSc1, Gonzalo Sánchez Benavides, PhD1, David Facal, PhD1, Bruno Dubois, MD, PhD1, Wiesje M. van der Flier, PhD1,2, Hanna Johinen, PhD1, Cristina Lojo-Seoane1, José Luis Molinuevo, MD, PhD1, Arturo X. Pereiro Rozas, PhD1, Craig Ritchie, MD, PhD1, Magdalini Tsolaki, MD, PhD1,2, Ya-Huei Wu, PhD1,2, Stelios Zygiouris, MSc1,2, Stephane Epelbaum, MD, PhD1,3, Philip Scheltens, MD, PhD1,4

Alzheimer Center, Department of Neurology, VU University Medical Center, Amsterdam Neuroscience, Amsterdam, the Netherlands, 1Department of Epidemiology and Biostatistics, VU University Medical Center, Amsterdam, the Netherlands, 2BercelonaBrain Research Center, Fundació Pasqual Maragall, Barcelona, Spain, 3Hospital Pitx-Salpêtrière, IM2A, PARIS, France, 4Department of Developmental Psychology, University of Santiago de Compostela, Spain, 5Clinical Neurosciences, Neurology, University of Helsinki and Helsinki University Hospital, Finland, 6University of Edinburgh, United Kingdom, 7F Institute of Neurology, University of Thessaloniki, Greece, 8Greek Association of Alzheimer’s Disease and Related Disorders, Greece, 9Boca Hospital, Paris, France, 10Nursing Aging Research, University of Heidelberg, Germany

Susan Abushafr1, Bruno Veillas MD1,2, Serge Gautier MD1,2, Anton Porsteinssohn MD1,2, Carl Sadowsky MD1,2, Aidan Power MD1,2, Larry Shen PhD1,2, Lu Wang MS1,2, Tim Lin MS1,2, John Hey PhD1, Martin Tolar MD PhD1,2
*Alzheimer, Inc., Framingham, MA, USA, 1University of Toulouse, Toulouse, France, 2McGill University, Montreal, Canada, 3University of Rochester, Rochester, New York, 4Palm Beach Neurology and Nova SE University, Fort Lauderdale, Florida, 5Pharmapace, Inc., San Diego, CA

Ana Espinosa, PhD1, Begoña Hernández-Olasagare, PhD1, Sonia Moreno-Grau, MSc1, Luca Kleineidam, MSc1,2, Stefanie Heilmann, PhD1,2, Isabel Hernández, MD, PhD1,2, Steffen Wolfrugbr, Dipl.-Psych.1, Holger Wagner, MSc1,2, Maike Rosende-Roca, MD1, Ana Mauleón, MD1,2, Liliana Vargas, MD1, Asunción Lafuente, MD1,3, Ociavio Rodríguez-Gómez, MD1, Carla Abdelnour, MD1, Silvia Gil, MD, PhD1, Marta Marquié, MD, PhD1, Miguel A. Santos-Santos, MD, PhD1, Ángela Sanabria, MSc1,2, Gemma Ortega, PhD1,2, Gemma Monté, PhD1,2, Alba Pérez, MSc1,2, Marta Ibarria, MSc1,2, Susana Ruiz, MSc1,2, Johannes Kornhuber, MD1,2, PhD1,2, Oliver Peters, MD1,2, Lutz Fröhlich, MD, PhD1,2, Michael Hüll, MD1,2, Jens Wiltfang, MD1,2, Martin Scherer, MD1, Tobias Luch, Dipl.-Psych.1,2, Steffi Riedel-Heller, MD1,2, Laura Montrell, MSc1, Pilar Cañabate, PhD1,2, Mariola Moreno, MSc1,2, Silvia Preckler, MSc1,2, Begoña Hernández-Olasagare, PhD1,2, Isidoro Nieves, MD1,2, John Hey Phd1, Martin Tolar MD Phd1,2
1Division of Geriatric Medicine, Dalhousie University, Halifax, NS, Canada, 2DGI Clinical Inc., Halifax, NS, Canada

CTAD 2018 POSTERS PRESENTATION
P143 - Baseline characterization of the European prevention of Alzheimer’s dementia (EPAD) longitudinal cohort study (LCS)
Michael T. Rapach, PhD, John Harrison, PhD1, Joel Kramer, PsyD1, Christopher Randolph, PhD1, Jeffrey Kaye, MD1, Bruce Albaugh, PhD2, Karen Ritchie, PhD3
1Strategic Global Research & Development, Half Moon Bay, USA, 2Metis Cognition Ltd, UK, 3Alzheimer Center VUmc, Amsterdam, Netherlands, 4Department of Neurology Memory and Aging Center, University of California at San Francisco, San Francisco, USA, 5Department of Neurology, Loyola University Medical Center, Maywood, USA, 6Neurolgy and Biomedical Engineering, Oregon Health and Science University, Portland, USA, 7Institut National de la Santé et de la Recherche Médicale, U1061 Neuropsychiatre, Montpellier, France, 8Faculty of Medicine, University of Montpellier, Montpellier, France, 9Center for Dementia Prevention, University of Edinburgh, Edinburgh, UK

P144 - Two distinct modelling approaches of cognitive decline and time to diagnosis of MCI/dementia to inform study design and to improve risk prediction in preclinical Alzheimer’s Disease
Angelika Caputo, PhD1, Ana Graf, MD1, Cristina Lopez Lopez, PhD1, Valery Risson, PhD1, Giulia Lestini, PhD1, Neva Coello, PhD1, Amy Racine, PhD1, Ines Paule, PhD1, Luyuan Qi, PhD1, Helene Karcher, PhD1
1Novartis Pharma AG, Basel, Switzerland, 2Analytica Laser, a Centara company, Paris, France, 3Analytica Laser, a Centara company, London, UK

P146 - Comparison of sleep measurements from actigraphy to self-reported sleep diaries
Kiri Kinnunen PhD1, Richard Joules, PhD1, Janet Munro, MPH1, John Simpson PhD2, Robin Woff, PhD2, Yves Davuilliers, MD PhD3
1IXICO Plc, London, UK, 2Imperial College London, London, UK, 3Sleep Unit, Department of Neurology, Centre Hospitalier Universitaire, Montpellier, INSERM U1061, France

P147 - Using DCTclocch’s clinically-interpretable artificial intelligence for differentiating cognitively healthy subjects from amnestic Mild Cognitive Impairment and probable Alzheimer’s Disease
William Souillard-Mandar1, Braydon Schaible1, Randall Davis PhD2, Rhoda Au PhD3, Dana Penney PhD2A
1Digital Cognition Technologies, Inc., Waltham, MA, USA, 2MIT Computer Science and Artificial Intelligence Laboratory, Cambridge, MA, USA, 3Boston University Schools of Medicine and Public Health, Boston, MA, USA, 4Lahey Hospital and Medical Center, Burlington, MA, USA

P148 - Advancing Clinical and Biomarker Research in AD: The LEAD Study
Lliana G. Apostolova, MD1, Paul Aisen, PhD1, Ani Eloyan, PhD1, Anne Fagan, PhD1, Tatiana Foroud, PhD1, Constantine Gatsonis, PhD1, Clifford Jack, MD1, Joel Kramer, PsyD1, Robert Koeppie, PhD1, Andrew Saykin, PsyD1, Arthur Toga, PhD1, Prashanthi Vemuri, PhD1, Gregory Day, MD1, MSc1, Neill Graff-Radford, MD1, Lawrence Honig, MD1, David Jones, MD1, Sterling Johnson, PhD1, Joseph Masdeu, MD1, Mario Mendez, MD1, Chiadi Onyike, MD1, Emily Rogalski, PhD1, Steve Salloway, MD1, David Wolk, MD1, Thomas Wingo, MD1, Maria Carrillo, PhD1, Brad Dickerson, MD1, Gil Rabinovi, MD1

P149 - Measuring Pre-Clinical Cognitive Decline over Time: Separating and Combining Alzheimer’s Specific Decline and Cognitive Decline Related to Aging in Cognitive Composite Scores
Suzanne Hendrix, PhD1, Noel Ellison, MSc1, Jessica B. Langbaum, PhD1, Kewei Chen, PhD1 and David A. Bennett, MD4
1Penfara Corporation, Milpopet, UT, USA, 2Arizona Alzheimer’s Consortium, Phoenix, AZ, USA, 3University of Arizona, Tucson, AZ, USA, 4Rush University, Chicago, IL, USA

Late Breaking Posters

LBP41 - Effects of 2-year walnut supplementation on cognitive decline in healthy elders: The Walnuts And Healthy Aging (WAHA) study
Nina Coli-Padros1, Aleix Sala-Vila1,2, Cinta Valls-Pedret3, Mercè Serra-Mir3, Montserrat Cofán3, Irene Roth4, Tania Freitas-Simoes5, Mónica Domènech6, Lidia Vaqué-Alcázar7, David Barrérs-Faz8, Sujatha Rajaram9, Joan Sabaté10, Emilio Ros11
1Alzheimer Disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clinic and Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain, 2Lipid Clinic, Endocrinology and Nutrition Service, Hospital Clinic, Barcelona, Spain, 3CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN), Instituto de Salud Carlos III (ISCIII), Spain, 4Institut de Neurociències i Facultat de Medicina i Ciències de la Salut, Universitat de Barcelona, Barcelona Spain, 5School of Public Health, Loma Linda University, Loma Linda, CA, USA

LBP42 - ADCOMS: a post-hoc analysis using data from the LipiDiDiet trial in prodromal Alzheimer’s disease
Suzanne B. Hendrix, PhD1, Hilkka Soininen, MD, PhD2,3, Pieter Jelle Visser, PhD4, Alina Solomon, MD, PhD5,6, Mia Kivipelto, MD, PhD7,8,9, Tobias Hartmann, PhD4,9 on behalf of the LipiDiDiet clinical study group
1Penfara Corporation, Salt Lake City, UT, USA, 2Department of Neurology, Institute of Clinical Medicine, University of Eastern Finland and Kuopio University Hospital, Kuopio, Finland, 3Neurocenter, Department of Neurology, Kuopio University Hospital, Kuopio, Finland, 4Department of Psychiatry and Neuropsychology, Alzheimer Center Limburg, University of Maastricht, Maastricht, the Netherlands, 5Department of Neurology, Alzheimer Center, VU University Medical Center, Amsterdam, the Netherlands, 6Department of Clinical Genetics, NSV, Karolinska Institute, Huddinge, Sweden, 7Clinical Trials Unit, Department of Geriatric Medicine, Karolinska University Hospital, Huddinge, Sweden, 8Deutsches Institut für Demenz Prävention (DIDP), Medical Faculty, Saarland University, Homburg, Germany, 9Department of Experimental Neurology, Saarland University, Homburg, Germany
LBP43 - Intraventricular Injection of Human Umbilical Cord Blood Mesenchymal Stem Cells in Patients with Alzheimer’s Disease Dementia: A Phase I Clinical Trial
Hee Jin Kim, MD, PhD,1 Kyung Rae Cho, MD,2 Hyemin Jang, MD, PhD,3 Jung Il Lee, MD, PhD,4 Seongbeom Park, MS,5 Soo Jin Choi,6 Sung Tae Kim, MD, PhD,7 Seung Hwan Moon, MD, PhD,8 Kyung-Han Lee, MD, PhD,9 Sang Won Seo, MD, PhD,10 Duk L. Na, MD, PhD4,8
Departments of 1Neurology, 2Neurosurgery, 3Radiology, and 4Nuclear Medicine Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, 5Neuroscience Center, Samsung Medical Center, Seoul, Korea, 6Biomedical Research Institute, MEDIPOST Co., Ltd, Seoul, Korea, 7Department of Clinical Research Design & Evaluation, SAIHST, Sungkyunkwan University, Seoul, Korea, 8Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul, Korea

LBP44 - Exploratory analysis of results from the NILVAD trial suggest benefit in very mild AD subjects
Michael Mullan, MBBS, PhD,1 Laila Abdullah, PhD,2 Heather Langlois,3 Fiona Crawford, PhD,3 Anders Wallin, MD,3 Suzanne Hendrix, PhD,4 Kaj Blennow, MD, PhD,3 Brian Lawlor, MBBS.5 The NILVAD consortium
1Archer Pharmaceuticals, Sarasota, FL, USA, 2Roskamp Institute, Sarasota, FL, USA, 3Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, Sweden, 4Pentara Corporation, Salt Lake City, UT, USA, 5Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital/Mölndal, Mölndal, Sweden, 6Trinity College Dublin, Dublin, Ireland

LBP45 - Can digital footprints capture clinically relevant gait endpoints in non-clinically setting: a Proof of Concept
Marie Mc Carthy1, Crystal Gon2
1ICON PLC, Dublin, Ireland, 2Trinity College Dublin, Ireland

LBP46 - Using the power of Dementias Platform UK (DPUK) cohorts to investigate the longitudinal effects of childhood adversity on adult cognition and health outcomes: implications for cognitive change and dementia outcomes
Sarah Bauermeister, PhD and John Gallacher, PhD
University of Oxford, Department of Psychiatry, Oxford, UK
Theme 6. Cognitive assessment and clinical trials

P6 - Evaluation of titers of antibodies against peptides of subunits NR1 and NR2B of glutamate receptor by enzyme-linked immunosorbent assay in psychiatric patients with anti-thyroid antibodies
Tatiahiro Iituka, MD, PhD, Yotohamacity University Psychiatry

P14 - Anosognosia in Mild Cognitive Impairment and Dementia
Dong Won Yang, Ahro Kim, Dong Woo Lee, Hyun Jeong Han, Jee Hyang Jeong, Jun Hong Lee, Jun-Young Lee, Kee Hyung Park, Kyung Won Park, SangYun Kim, Seong Hye Choi, Young Chul Youn
Department of Neurology, Catholic University of Korea, Seoul, Korea, Department of Psychiatry, Inje University Sanggye Path Hospital, Seoul, Korea, Department of Neurology, Myongji Hospital, Goyang, Department of Neurology, Ewha Womans University Mokdong Hospital, Ewha Womans University School of Medicine, Seoul, Department of Neurology, National Health Insurance Corporation Ilsan Hospital, Goyang, Department of Psychiatry and Neuroscience Research Institute, Seoul National University College of Medicine 65C, SNU Boramar Medical Center, Seoul, Republic of Korea, Department of Neurology, Gachon University Gil Hospital, Incheon, South Korea, Department of Neurology, Dong-A University College of Medicine, Busan, South Korea, Department of Neurology, Seoul National University Bundang Hospital, Seongnam, South Korea, Department of Neurology, Inha University School of Medicine, Incheon, South Korea, Department of Neurology, Chung-Ang University Hospital, Seoul, Korea

P24 - Clinical correlates of types of memory complaints in mild cognitive impairment
Seon Young Ryu, MD, PhD, Sang Bong Lee, MD, PhD, Taeh Jun Lee, MD, Yu Jin Jung, MD, PhD
Neurology Department, Daejeon St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Daejeon, South Korea

P29 - A comparison between brief episodic memory and semantic memory tasks within a screening test for mild cognitive impairment
Pamela Voccia Eds, Katherine Kruczelt, MS
Bioclinica Research, The Villages, FL, USA

P33 - Comparative evaluation of tests for the cognitive dysfunction screening in the national medical check-up
Ahro Kim, Dong Won Yang, Dong Woo Lee, Hyun Jeong Han, Jee Hyang Jeong, Jun Hong Lee, Jun-Young Lee, Kee Hyung Park, Kyung Won Park, SangYun Kim, Seong Hye Choi, Young Chul Youn
Department of Neurology, Seoul St. Mary’s hospital, Catholic University of Korea, Seoul, Korea, Department of Psychiatry, Inje University Sanggye Path Hospital, Seoul, Korea, Department of Neurology, Myongji Hospital, Goyang, Department of Neurology, Ewha Womans University Mokdong Hospital, Ewha Womans University School of Medicine, Seoul, Department of Neurology, National Health Insurance Corporation Ilsan Hospital, Goyang, Department of Psychiatry, Seoul National University Boramar Hospital, Seoul, Korea, Department of Neurology, Gachon University Gil Hospital, Incheon, South Korea, Department of Neurology, Cognitive Disorders and Dementia Center, Dong-A University College of Medicine and Institute of Convergence Bio-Health, Busan, South Korea, Department of Neurology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea, Department of Neurology, Inha University School of Medicine, Incheon, South Korea, Department of Neurology, Chung-Ang University Hospital, Seoul, Korea

P41 - Cognitive impairment under treatment with 2nd and 3rd generation antihistamines in elderly subjects
Georg Adler, Nadja Baumgart
Institut für Studien zur Psychischen Gesundheit, Mannheim, Germany

P42 - Using Bayesian methods to model normative CANTAB cognition data across adulthood
Pasquale Dente, Elizabeth Baker, Jack Cotter, Francesca Cormack, Jennifer H Barnett
Cambridge Cognition Limited, Cambridge, UK, University of Cambridge, Cambridge, UK

P47 - Predicting the course of Alzheimer’s
Samuel Iddi, PhD, Dan Li, PhD, Wesley K Thompson, PhD, Michael S. Rafii, MD, PhD, Paul S. Aisen, MD, and Michael C Donohue, PhD
ATRI, University of Southern California, San Diego, CA, United States, Department of Family Medicine and Public Health, University of California, San Diego, USA, Department of Statistics, University of Ghana, Legon-Accra, Ghana

P48 - Impaired delayed recall on the International Shopping List Task predicts amyloid positivity and longitudinal decline in CDR-SB scores in MCI
Sharon Rosenzweig-Lipson, PhD, Richard Mohs, PhD, Paul Maruff, PhD, Michela Gallagher, PhD and Arnold Bakker, PhD
Agenetico, Inc., Baltimore, MD, USA, Cogstate, Ltd, Melbourne, Victoria, Australia, Johns Hopkins University, Baltimore, MD, USA

P49 - MMSE screening data quality for Alzheimer’s disease studies across countries
Jordan Mark Barbone, BA, Todd M. Solomon, PhD, H. Todd Feaster, PsyD, Macarena Garcia-Valdecasas Colell, MSc, David S. Miller, MD, MA
Brachet, Wayne, PA, USA, Boston University School of Medicine, Boston, MA, USA, Brachet, Reading, UK
P50 - Affective variability predicts cognitive fluctuation and decline in older adults
Edward Zamrini, MD, Michael Maleah- Ahmad, PhD, Kathy O’Connor, Sharon Schofield
Banner Sun Health Research Institute, Sun City, USA, Banner Alzheimer’s Institute, Phoenix, USA

P51 - Validation of the geriatric depression scale in the elderly Korean with Alzheimer’s disease
Moon Ho PARK, MD, PhD, Do-Young KWON, MD, PhD
Department of Neurology, Korea University Ansan Hospital, Ansan, South Korea

P52 - Can TMT-black and white predict the white matter hyperintensity of MRI in the community based elderly?
Young Chul Youn, MD, PhD
Neurology Department, Chung-Ang University College of Medicine, Seoul, Korea

P55 - CANTAB tests predict change in global functioning in patients with amnestic mild cognitive impairment
Elizabeth Baker PhD, Peter Annas PhD, Giovanni B. Frisoni, MD, PhD, David Bantres-Faz, MD, PhD, Beatriz Bosch PhD, Jose Luis Molinuevo, MD, PhD, Mira Didic, MD, PhD, Francesco De Anna, Lucilla Parnetti, MD, PhD, Nicola Salvadori PhD, Jens Wilflang, MD, PhD, Flavio Nobili, MD, PhD, Nicola Girnert, PsyD, Peter Schönle, MD, PhD, Pieter J. Visser, MD, PhD, Paolo M. Rossini, MD, PhD, Paola Chiavenda, MA, Pierre Payoux, MD, PhD, Andrea Sorricelli, MD, PhD, Marco Salvarote, PhD, Magda Tsohali, MD, PhD, Jill C. Richardson, PhD, Régis Bordet, MD, PhD, Olivier Blin, MD, PhD, Gianluigi Forloni on behalf of the PharmaCog Consortium

P63 - Validating simulated cognition trajectories based on ADNI against trajectories from the National Alzheimer’s Coordinating Center (NACC) dataset
Ali Tafazzoli, PhD, Josh Weng, PhD, Kelly Sutton, PhD, Michal Litwichev, MSc, Ameya Chavan, BS, Mira Krotneva, MSc, Anuraag Kansal, PhD
Evidera, Bethesda, MD, USA, Evidera, Waltham, MA, USA, Evidera, London, UK, Evidera, Montreal, Canada

P68 - Recruitment using the DCTclockTM
Daniel Lawler, MD, Stephen Thein PhD
Pacific Research Network Inc, San Diego, CA, USA

P70 - Strategy or symptom: clustering and risk of Alzheimer’s disease
Jamie Ford, MSc, Bang Zheng, MSc, MD, Barbara Hurtado, M.A, CPsychol, Chi Udeh-Momoh, MSc, PhD, Geraint Price, MSc, D Clin Psy
Imperial College London, UK

P72 - Tau is associated with longitudinal memory decline in healthy subjects: the need for an early detection of subtle cognitive changes
Adria Tort-Merino, MSc, Jaime Olives, MSc, Maria León, MSc, Claudia Peñaloza, PhD, Natalia Valech, MSc, Petra Grönholm-Nyman, PhD, Pablo Martínez-Lage, MD, PhD, Juan Fortea, MD, PhD, José Luis Molinuevo, MD, PhD, Raquel Sánchez-Valle, MD, PhD, Matti Laine, PhD, Antoni Rodríguez-Fornells, PhD, Lorena Rami, PhD
Alzheimer’s Disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clinic, Barcelona, Spain, Cognition and Brain Plasticity Group, Bellvitge Biomedical Research Institute- IDIBELL, L’Hospitalet de Llobregat, Barcelona, Spain, Department of Psychology, Ábo Akademi University, FIN-20500 Turku, Finland, Neurología, Fundación CITA-Alzheimer, Fundación, Centro de Investigación y Tecnologías Avanzadas, San Sebastián, Guipúzcoa, España, Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau and Institute of Biomedical Research, Barcelona, Spain, Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas, CIBERNED, Spain, Barceloneta Brain Research Center, Pau Casals Maragall Foundation, Barcelona, Spain, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona, Spain, Catalan Institution for Research and Advanced Studies (ICREA), Barcelona, Spain, Department of Cognition, Development and Education Psychology, Campus Bellvitge, University of Barcelona, L’Hospitalet de Llobregat, Barcelona, Spain

P75 - Flunks and flukes: recognising unrepresentative performance on cognitive tests
Geraint Price, D Clin Psy, Bowen Su, MD
Imperial College London, UK
P87 - Assessing decline in visuospatial working memory associated with subjective cognitive impairment using a tablet-based measure of hippocampal-dependent learning
Alexandra S. Atkins1, Anzalee Khan1, Daniel Ushen1, John Harrison1, Brenda L. Plassman2, Kathleen A. Welsh-Bohmer2 & Richard S.E. Keefe2
1NeuroCog Trials, Durham, NC, 2Alzheimer Center, YUmc, Amsterdam, The Netherlands
King’s College, London, UK, 3Duke University Bryan ADRC, Durham, NC, 4Duke University Medical Center, Durham, NC, 5Duke University Medical Center, Durham, NC

P88 - Severe cognitive impairment in older adult heart failure patients: Preliminary findings from the Deus ex Machina study
Emília Moreira, Psy, MPH, PhD1, Sónia Martins, Psy, PhD2, Luís Filipe Azevedo, MD, PhD3, José SilvaCardoso, MD, PhD4,5, Lia Fernandes, MD, PhD1,2,6
1Center for Health Technology and Services Research/CINTESIS, Faculty of Medicine, University of Porto, Portugal, 2Department of Clinical Neurosciences and Mental Health, Faculty of Medicine, University of Porto, Portugal, 3Department of Community Medicine, Information and Health Decision Sciences/MEDCIDS, Faculty of Medicine, University of Porto, Portugal, 4Department of Medicine, Faculty of Medicine, University of Porto, Portugal, 5Department of Cardiology S. João Hospital Center, Porto, Portugal, 6Clinic of Psychiatry and Mental Health, S. João Hospital Center, Porto, Portugal

P89 - The effect of dizziness in patients with cognitive impairments
Seunghae Na, MD, In-Uh Song, MD, PhD
Department of Neurology, Incheon St. Mary’s Hospital, the Catholic University of Korea, Incheon, Korea

P151 - Selection of depression-specific dementia cases with replication in two cohorts
Donald R. Royall, MD1,4, Raymond F. Palmer, PhD2
1Department of Psychiatry, The University of Texas Health Science Center at San Antonio (UTHSCSA), San Antonio, Texas, USA, 2Department of Medicine, UTHSCSA, San Antonio, Texas, USA, 3Department of Family & Community Medicine, UTHSCSA, San Antonio, Texas, USA, 4South Texas Veterans Health Administration Geriatric Research Education and Clinical Center (GRECC), San Antonio, Texas, USA

P152 - Selection of depression-specific dementia cases with replication in two cohorts
Donald R. Royall, MD2,4, Raymond F. Palmer, PhD2
1Department of Psychiatry, The University of Texas Health Science Center at San Antonio (UTHSCSA), San Antonio, Texas, USA, 2Department of Medicine, UTHSCSA, San Antonio, Texas, USA, 3Department of Family & Community Medicine, UTHSCSA, San Antonio, Texas, USA, 4South Texas Veterans Health Administration Geriatric Research Education and Clinical Center (GRECC), San Antonio, Texas, USA

P153 - Assessment and speech-language intervention program in Non-Fluent Primary Progressive Aphasia: A case study
Beatriz Valls-González1 & Vicent Rosell-Clari2
1Speech and Language Pathology Clinic. Lluís Alcanyís Foundation-Universitat de Valencia, 2Basic Psychology Department. Universitat de Valencia

P154 - Prediction of APOE ε4 Burden from Cognitive Assessment
Royall DR1,4, Palmer RP2 for the Alzheimer’s Disease Neuroimaging Initiative*
1Departments of Psychiatry, “Medicine, Family & Community Medicine, The University of Texas Health Science Center at San Antonio and the 2South Texas Veterans Health Administration Geriatric Research Education and Clinical Center (GRECC)

P155 - Could Telemedicine improve neurocognitive disorders detection and diagnosis in nursing home?
Armelle Leperre-Desplanques1, Isabelle Hauger2, Sylvain Gautier3, Antonis Politis3, Shima Mehrabian4, Audrey Maillet1, Pierre Krolab-Salmon1
1Clinical and Research Memory Centre, Lyon Institute for Elderly, Hospices Civils de Lyon, Inserm UMR1028, CNRS UMR 5292, Lyon University, France, 2Résidence Talassia, Tolence, France, 3National and Kapodistrian University of Athens, Athens, Greece, 4Clinic of Neurology, UH “Alexandrovskia”, Medical University, Sofia, Bulgaria

P156 - Cognitive Blackouts in Mild Cognitive Impairment of the Amnestic Type and mild Alzheimer’s Dementia
Georg Adler, Agnies Marcza2, Jana Binder, Katharina Gnosa
Institut für Studien zur Psychischen Gesundheit, Mannheim, Germany

P157 - Feasibility of the neuropsychological battery camcog-ds for the detection of cognitive decline in people with down syndrome
Laura Videla1,2,3 Bessy Benejam1, María Carmona-Iragui1,2,3, Susana Fernández1, Isabel Barroeta1,2,3, Sebastián Videla1, Alberto Lleo1,2, Rafael Blesa1,2, Juan Fortea1,2,3
1Alzheimer Unit - Donu, Donu Medical Center, Fundació Catalana Síndrome de Down, 2Memory Unit of the Neurology Service of the Hospital de la Santa Creu and Sant Pau, 3Biomedical Research Institute of Sant Pau, Universitat Autònoma de Barcelona, 4Central Biomedical Research Center (CIBERNED)

P158 - Distinct patterns of cognitive decline between early-onset Alzheimer’s disease and late-onset Alzheimer’s disease
Adrià Torr Merino, MSc1, Jaume Olives, MSc1, Neus Falgàs, MD1, Mircea Balasa, PhD1, Magda Castelví, MSc1, Sergi Borrego, MD1, Beatriz Bosch, PhD1, María León, MSc1, Ana Salinero, MSc1, Guadalupe Fernández, RN1, Anna Antonell, PhD1, Raquel Sánchez-Valle, MD, PhD1, Lorena Rami, PhD1, Albert Liado, MD, PhD1
1Alzheimer’s Disease and other Cognitive Disorders Unit, Neurology Service, Hospital Clinic, Barcelona, Spain
Late Breaking Posters

**LBP47** - Strategic Memory Alzheimers Rehabilitation Training (SMART) Memory Program for Amnestic Mild Cognitive Impairment (aMCI): Reporting the Results of a Randomized Clinical Trial

John W. DenBoer, Ph.D., SMART Brain Aging, Inc.

**LBP48** - Memory errors of commission rather than errors of omission discern aging and early Alzheimer’s disease

Matthias W. Riepe, MD, Claudia Lanza, PhD, Karolina Sejunaite, MS

Department of Psychiatry and Psychotherapy II, Mental Health & Old Age Psychiatry, Ulm University, Ulm, Germany

**LBP49** - Standard cognitive assessment in the era of biomarkers and disease-modifiers

Marina Boccardi, PsyD, PhD1, Stefano Cappa, MD, PhD1, Bruno Dubois, MD1, Jean Georges1, Matthias Kriegel, PsyD, PhD1, Bengt Winblad, MD, PhD1, David Salmon, PhD1, Giovanni Frisoni, MD1, Andrea Mensch, PsyD, PhD1, for the Tash Force for Harmonizing Neuropsychological Assessment for Dementia Neurodegenerative Disorders

LANNIE, Laboratory of Neuroimaging of Aging, University of Geneva, Geneva, Switzerland; IRCCS S.Giovanni di Dio, Fatebenefratelli, Brescia, Italy; Dementia Research Center, Hôpital Pitié-Salpêtrière, Paris, France; Alzheimer Europe, Laboratory of Cognitive Aging, University of Geneva, Geneva, Switzerland; Karolinska University Hospital, Stockholm, Sweden; Department of Neurosciences, University of California San Diego School of Medicine, United States; University of Basel, Basel, Switzerland

**LBP50** - Lanabecestat: Rater performance and error characteristics of efficacy assessments in the DAYBREAK-ALZ study

Aletta M. Wessels, PhD1, Jordan Marth Barbone, BA1, Danielle T. DiGregorio, PsyD2, David S. Miller, MD, MA2, Jamie A. Mullen, MD, BA, & John R. Sims, MD1

Eli Lilly and Company, Indianapolis, IN, USA, Brian T. Raye, Ph.D., USA, AstroZeneca Pharmaceuticals, Cambridge, MA, USA

**LBP51** - iPSC model of CHRFAM7A effect on a7 nicotinic acetylcholine receptor function may explain the translational gap in drug development

Ivana Ihnatowycz1, Tapan Nayak1, Aya Ouf2, Norbert Sule1, Barbara Birkhaya1, Lee Chaves1, Anthony Auerbach1

SUNY at Buffalo, Roswell Park Cancer Institute

**LBP52** - Effects of Age and CSF measures of Tau on Mnemonic Discrimination of Objects and Scenes in Medial Temporal Lobe Pathways

David Berron, PhD1,2, Arturo Cardenas-Blanco, PhD1, Daniel Bittner, MD2, Coraline D. Metzger, MD, PhD1, Annila Spotche, MD1, Michael Henhe, MD1, Klaus Fiedtbach, MD1, Anja Schneider, MD1, Stefan J. Teipel, PhD, MD1,2, Michael Wagner, PhD1,2, Oliver Speckt, Prof. Dr.2, Dr. Frank Jessen, MD, Prof. Dr.1,2, Emrah Düze1, MD1,2, and the DELCODE study group

ClinicalMemory Research Unit, Department of Clinical Sciences Malmö, Lund University, Lund, Sweden; University Hospital Malmö, Malmö, Germany; German Center for Neurodegenerative Diseases, Malmö, Germany; German Center for Neurodegenerative Diseases (DZNE), Malmö, Germany; Institute of Cognitive Neurology and Dementia Research (INoD), Otto-von-Guericke University, Magdeburg, Germany; Department of Neurology, University Hospital of Born, Born, Germany; German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany; Department of Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital Born, Born, Germany; DZNE, German Center for Neurodegenerative Diseases, Bonn, Germany; Department of Psychiatry and Psychotherapy, University of Born, Born, Germany; Department of Psychosomatic Medicine, Rostoch University Medical Center, Rostoch, Germany; American Center for Neurodegenerative Diseases and Genotoxic Psychiatry, University Hospital, Born, Germany; Department of Biomedical Magnetic Resonance, Otto-von-Guericke University, Magdeburg, Germany; Department of Psychiatry, University Hospital Cologne, Cologne, Germany

**P159** - High level of plasmatic amyloid Aβ 1-40 increase the risk of cognitive decline in 3C study with 14 years of follow-up

Audrey Cabelle1, MD, Ph.D.1,2, Laure-Anne Gutierrez1, MSc1,2, Thibault Mura M.D, Ph.D1,2, Jean-François Dartigues, Ph.D1,3, Olivier Rouaud, MD1, Jean-Charles Lambert Ph.D.1,2,3, Catherine Helmer, Ph.D.1,2, Claudine Berr M.D, Ph.D1,2,3

1Memory Research and Resources Center, Montpellier University Hospital, Montpellier; 2Inserm U1061, La Calotomie Hospital, Montpellier; 3University of Montpellier, MUSE University, Montpellier; 4Bordeaux University, Inserm, Bordeaux Population Health Research Center, UMR 219, Bordeaux, France; 5CHU Bordeaux, Department of Public Health, F-33000 Bordeaux, France; 6CHRU Dijon, Centre Memoire Ressources et Recherche, Dijon, France; 7CHRU de Lille, Lille, France; 8INSERM U744, Lille, France; 9Institut Pasteur de Lille Nord de France, Lille, France

**P162** - Using graphical hierarchical bayesian cognitive process models applied to common memory tests to detect ad pathology within normal subjects

William R. Shankle1, MS, MD2,3, Junho Hara1, PhD2,3, Jason R. Boch, MA1, Dennis Fortier, MBA1, Tushar Mangroa, MS1, Michael Lee, PhD2, Gregory E. Alexander, PhD2, William H. Batchelder, PhD2, Ronald C. Petersen, MD, PhD1, Walter Kremers, PhDD

1Medical Care Corporation, Newport Beach, CA, USA; 2Dept. of Cognitive Sciences, University of California at Irvine, Irvine, CA, USA; 3Pickup Family Neuroscience Institute, Hoag Memorial Hospital, Newport Beach, CA, USA; 4Mayo Clinic, Rochester, MN, USA

**Poster Session**

CTAD 2018
Theme 7. Behavioral disorders and clinical trials

**P32 - Effect of memantine on behavioral and psychological symptoms of dementia (BPSD) of Alzheimer’s disease**
- Study of changes in cerebral blood flow by spect imaging

Aims

Kiyoshi Kanaya, MD, Geriatric medicine, Tokyo Medical University Hachioji medical center, Shine Abe, MD, Geriatric medicine, Tokyo Medical University Hachioji medical center

**P37 - Clusterization of behavioral and psychological symptoms of dementia (BPSD)**

Timofey L. Galantkin, MD, PhD, Anton Y. Bespalov, MD, PhD, Hans J. Moebius, MD, PhD

'EXCIVA, Am, Germany, +Valdman Institute of Pharmacology, Pavlov First Saint Petersburg State Medical University, St. Petersburg, Russia

**P43 - The effect of dizziness in patients with cognitive impairments**

Seunghee Na, MD, In-Uk Song, MD, PhD

Department of Neurology, Incheon St. Mary’s Hospital, the Catholic University of Korea, Incheon, Korea

**P163 - A multicenter, randomized trial to assess efficacy of Therapeutic Intervention Program for Dementia Caregivers (I-CARE)**

Jihye Hwang, MD, PhD, Geon-Ha Kim, MD, PhD, Hae-Ri Na, MD, PhD, Soo-Jin Cho, MD, PhD, Kyung-Ho Yu, MD, PhD, Do Hoon Kim, MD, PhD, Jae-Hong Lee, MD, PhD, Seong-Hye Choi, MD, PhD

Department of Neurology, Keimyung University School of Medicine, Department of Neurology, Ewha Womans University School of Medicine, Department of Neurology, Bobath Memorial Hospital, Department of Neurology, Hallym University School of Medicine, Department of Neurology, Inha University School of Medicine

**Late Breaking Posters**

**LBP53 - Prevalence of obstructive sleep apnea in Alzheimer’s disease patients**

Anna Carnes, PhD, Carme Jorge, MD, Benitez ID, Faride Dakterzada, Olga Minguez, Raquel Huerto, Montse Pujol, MD, PhD, Anna Gaeta, MD, Alfonso Arias, MD, Aurora Gibert, Manuel Sanchez de la Torres, MD, PhD, Ferran Barbé, MD, PhD, Gerard Piñol-Ripoll, MD, PhD

Unitat Trastorns Cognitius, Clinical Neuroscience Research, IRBLleida-Hospital Universitari Sant Joan de Reus, Sant Joan de Reus, Spain, “Group of Translational Research in Respiratory Medicine, Hospital Universitari Anna de Villanova and Santa Maria, IRBLleida, Lleida, Spain, “Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Madrid, Spain
P17 - Effect of physical activity on the progression of Alzheimer’s disease: the CREDOS study
Seong Hye Choi1, Jee Hyang Jeong2, Eun-Joo Kim3, Kyung Won Park4, Bora Yoon5, Soo Jin Yoon6, Yang-Ki Min7, Young Ju Suh8

1Department of Neurology, Inha University School of Medicine, Incheon, South Korea, 2Department of Neurology, Ewha Womans University School of Medicine, Seoul, South Korea, 3Department of Neurology, Pusan National University School of Medicine, Busan, South Korea, 4Department of Neurology, Dong-A University College of Medicine, Busan, South Korea, 5Department of Neurology, College of Medicine, Konkuk University, Daejeon, South Korea, 6Department of Neurology, Eulji University School of Medicine, Daejeon, South Korea, 7Department of Neurology, Hallym University Kangnam Sacred Heart Hospital, Hallym University College of Medicine, Seoul, South Korea, 8Department of Biomedical Sciences, Inha University School of Medicine, Incheon, South Korea

P40 - The Survey for Current State and Dognition of Activities of Daily Living in Korean dementia patients
Kee Hyung Park, MD, PhD1, Chan-Nyoung Lee, MD, PhD2, Hojin Choi, MD, PhD3

1Department of Neurology, Gachon University, Gil Medical Center, Incheon, Korea, 2Department of Neurology, Korea University College of Medicine, Seoul, Korea, 3Department of Neurology, Hanyang University Guri Hospital, Guri, Korea

P58 - Young onset diseases care pathways. Parcours des malades Alzheimer et apparentés jeunes - PARMAAJ
Adeline Rollin-Sillaire, MD1,2, Brigitte Leprince3, Catherine Adnet-Bonte, MD1, Laetitia Breuilh, PhD2, Florence Pasquier, MD, PhD3

1Centre National de Référence des Malades Alzheimer Jeunes, Neurology Department, Centre Hospitalier Universitaire de Lille, France, 2Excellence Laboratory DISTALZ, Inserm U117, Univ Lille, 3Medis, Centre Hospitalier Universitaire de Lille, France

P164 - Dutch online registry for recruitment of participants for dementia studies
Marissa D. Zwan, PhD1, Derek Flenniken2,3, Shannon Finley, MA2, Aaron Ulbricht2,3, Rachel Nosheny, PhD2,3, Wiesje M. van der Flier, PhD1, Philip Scheltens, MD, PhD1, Diana Truran-Sacrey2, Michael W. Weiner, MD2,3, Niels D. Prins, MD, PhD1

1Alzheimer Center & Department of Neurology, Neuroscience Campus Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands, 2Center for Imaging of Neurodegenerative Diseases, San Francisco Veteran’s Administration Medical Center, San Francisco, USA, 3UCSF Department of Radiology and Biomedical Imaging, San Francisco, USA
Theme 9. Epidemiology and clinical trials

P27 - Awareness of Alzheimer’s dementia as their own disease in Asian Countries
San Jung, YongSoo Shim, SangYun Kim
Department of Neurology, Hallym University Medical Center, Kang Nam Sacred Heart Hospital, Seoul, Korea, Department of Neurology, College of Medicine, The Catholic University of Korea, Bucheon St. Mary’s Hospital, Seoul, Korea, Department of Neurology, Seoul National University College of Medicine & Neuroscience Center, Seoul National University Bundang Hospital, Seoul, Korea

P38 - Subjective memory complaints are related to the social participation and leisure activities: TOyoake Integrated Care Study (TOICS)
Hajime Tabechi, MD, PhD1, Atsuko Tsuzuki, RPT, DMSc2, Komachi Matsumoto, Ms3, Hiroyuki Nishiyama, Mr4, Masatoshi Ogawa, Mr5, Yoshitoyo Kanada, RPT, DMSc2
Department of Geriatrics and Cognitive Disorders, School of Medicine, Fujita Health University, Aichi, Japan, 2Department of community care, TOyoake city municipal office, Aichi, Japan, 3Gusle Corporation, Tokyo, Japan

P46 - Alzheimer’s disease drug development pipeline: 2018
Jeffrey Cummings, MD, ScD1, Garam Lee, PharmD1, Aaron Ritter, MD2, Kate Zhong, MD2
1Cleveland Clinic Lou Ruvo Center for Brain Health, Las Vegas, NV, USA, 2Global Alzheimer Platform, Washington, D.C., USA

P165 - Association between amyloid status and multiple chronic diseases in European Prevention of Alzheimer’s Disease (EPAD): network and cluster analyses
Lucy E Stirling, MBChB, MRCPsych1, Tom C Russ MBChB, PhD, MRCPsych2, Graciela Muniz Terrera, PhD3, Craig W Ritchie MBChB, PhD, MRCPsych1
1Centre for Dementia Prevention, University of Edinburgh, Edinburgh, UK, 2Alzheimer Scotland Dementia Research Centre, Edinburgh, UK

P166 - Concord-AD: An International Network of Cohorts for Better Understanding Alzheimer’s Disease
Samantha C Bunnam, PhD1, Preciosa M Coloma, MD, PhD2, Teresa J. Christainson3, BS, Jean-François Dartigues, MD, PhD4,6, Rachelle Doody, MD, PhD5, Oshar Hansson, MD, PhD5, Catherine Helmer, MD, PhD5,6, Joseph S Kass, MD, JD5, Colin L Masters, MD5,6, Sebastian Paltomqvist, MD, PhD5,6, Valory N Pavlih, PhD4, Ronald C. Petersen, MD, PhD1,2, Rosebud O. Roberts, MB CHB, MS4,5,6, Maria Vassilaki, MD, MPH, PhD5,6, Barbara Schauble6 and Mary Sano, Ph.D.1,4,5
1eHealth, CSIRO Health & Biosecurity, Melbourne, Australia, 2Product Development Personalised Health Care, Data Science, F. Hoffmann-La Roche Ltd., Basel, Switzerland, 3Department of Neurology, Mayo Clinic, Rochester, MN, USA, 4Bordeaux University, Bordeaux, France, 5INSERM, ISPED, Centre INSERM U897-Épidémiologie-Biostatistique, Bordeaux, France, 6F. Hoffmann-La Roche Ltd, Basel, Switzerland, “Clinical Memory Research Unit, Lund University, Malmö, Sweden, (B)INSEMR UB97, BORDEAUX, France, Baylor College of Medicine, Houston, TX, USA, 12The Florey Institute of Neuroscience and Mental Health, Parkville, Australia, 1Department of Neurology, St. Joseph University Hospital, Lund, Sweden, “Department of Health Sciences Research, Division of Epidemiology, Mayo Clinic, Rochester, MN, USA, 7Product Development Medical Affairs, F. Hoffmann-La Roche Ltd., Basel, Switzerland, “Department of Psychiatry, Alzheimer’s Disease Research Center, Icahn School of Medicine at Mount Sinai, New York, NY, USA, 8James J. Peters VA Medical Center, Bronx, NY, USA

P167 - Cognitive and brain structural correlates of insomnia symptoms in middle-aged healthy adults
Oriol Grau-Rivera1, Juan Domingo Gispert1,2, Grégory Operto2, Carles Falcon3,4, Raffaele Cacciaglia1, Gonzalo Sánchez-Benavides1, Anna Buglai1,6, Dora Papp1, Gemma Salvado1, Marc Suárez-Calvet2, Carolina Minguillón3, Karine Fauria4, José Luis Molinueto13,4
1BarcelonaLlobregat Brain Research Center, Catalunya, Spain, 2Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Zaragoza, Spain, 3CIBER Frailidad y Envejecimiento Saludable (CIBERFES), Madrid, Spain, 4Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Catalunya, Spain

P168 - A Phase II randomized clinical trial of high-dose versus standard-dose Vitamin D3 in an ethnically diverse sample of older adults
John Olichney, MD1, Charlie DeCarli, MD1, Joshua W Miller, PhD2, David Johnson, PhD2, Sarah Tomaszewski-Farias, PhD2, Bruce Hammon, PhD3, Brittany Dugger, PhD4, Lee-Way Jin, MD, PhD5, Mary McPhail-Ciuflo, DO6, Robert Soohoo, BS5, Dan Mungas, PhD7, Danielle Harvey, PhD8
1Neurology Department, University of California Davis, Sacramento, CA, USA, 2Department of Nutritional Sciences, Rutgers, The State University of New Jersey, New Brunswick, NJ, 3Department of Entomology & Comprehensive Cancer Center, University of California Davis, Davis, CA, USA, 4Pathology Department, University of California Davis, Sacramento, CA, USA, 5Psychology Department, University of California Davis, Davis, CA, USA, 6Department of Public Health Sciences, University of California Davis, Davis, CA, USA

Late Breaking Posters

LBP54 - Psychometric methodologies to increase scale-reliability in dementia-focused epidemiology: Outcomes from the European Prevention of Alzheimer’s Disease Study and UK Biobank
Sarah Bauermester, PhD and John Gallacher, PhD
University of Oxford, Department of Psychiatry, Oxford, UK
LBP55 - STOPBANG and Berlin Questionnaire as screening tools to identify obstructive sleep apnea in Alzheimer’s disease
Anna Carnes, PhD1, Benitez ID12, Faride Dakterzada1, Olga Minguez2, Raquel Huerto1, Montse Pujol1, MD, PhD, Anna Gaeta, MD2, Alfonso Arias1, MD, Aurora Gibert1, Manuel Sanchez de la Torres12, MD, PhD, Ferran Barbé23, MD, PhD, Gerard Piñol-Ripoll1, MD, PhD

1Unitat Trastorns Cognitius, Clinical Neuroscience Research, IRBLleida-Hospital Universitari Santa Maria, Lleida, Spain, 2Group of Translational Research in Respiratory Medicine, Hospital Universitari Arnau de Vilanova and Santa Maria, IRBLleida, Lleida, Spain, 3Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBEREBS), Madrid, Spain

LBP56 - Exposure to benzodiazepines and development of Alzheimer’s disease: a cohort study in a Health Region of Catalonia between 2002 and 2015
Carnes A1, Torres-Bondia, FI1, de Batlle J2, Piñol-Ripoll, G1

1Unitat Trastorns Cognitius, Clinical Neuroscience Research, IRBLleida-Hospital Universitari Santa Maria Lleida, Spain, 2Group of Translational Research in Respiratory Medicine, Hospital Universitari Arnau de Vilanova and Santa Maria, IRBLleida, Lleida, Spain
Theme 10. Animal model and clinical trials

PI02 - Concussive head injury exacerbates Alzheimer’s disease brain pathology. Superior neuroprotection by Co-administration of TiO2 nanowired Cerebrolysin together with antibodies to neuronal nitric oxide synthase and mesenchymal stem cells

Hari Shanker Sharma*, José V Lafuente1, Dafin F Muresanu2, Rudy J Castellani3, Mark A Smith4, Ala Nozari5, Ranjana Patnaik6, Z Ryan Tian7, Asya Ozhizilic8, Stephen D Shaper9, Herbert Mössler10, Aruna Sharma1

International Experimental CNS Injury & Repair (IECNSIR), Laboratory of Cerebrovascular Research, Dept. of Surgical Sciences, Anesthesiology & Intensive Care Medicine, Uppsala University Hospital, Uppsala University, Uppsala, Sweden, 1Dept of Neurosciences, University of Basque Country, Bilbao, Spain, 2Dept. Clinical Neurosciences, University of Medicine & Pharmacy, Cluj-Napoca, Romania, 3“RobNeuro” Institute for Neurological Research and Diagnostic, Cluj-Napoca, Romania, 4University of Maryland, Dept. of Pathology, Baltimore, MD, USA, 5Case Western Reserve Medical University, Dept. of Pathology, Cleveland, OH, USA, 6Anesthesiology, Massachusetts General Hospital, Harvard University, Boston MA, USA, 7School of Biomedical Engineering, Dept. of Biomaterials, Indian Institute of technology, Banaras Hindu University, Varanasi, India, 8Dept. Chemistry & Biochemistry & Biomedical Engineering, University of Arkansas, Fayetteville, AR, USA, 9Department of Pharmacology and Anesthesiology, University of Padua, Faculty of Medicine, Padua, Italy, 10Ever NeuroPharma, Oberburgau, Austria

PI03 - Sleep deprivation aggravates Alzheimer’s disease brain pathology. Enhanced neuroprotection by nanowired delivery of cerebrolysin with alpha melanocyte stimulating hormone and antibodies to alpha-synuclein

Aruna Sharma*, José V Lafuente1, Dafin F Muresanu2, Rudy J Castellani3, Mark A Smith4, Ala Nozari5, Ranjana Patnaik6, Z Ryan Tian7, Asya Ozhizilic8, Herbert Mössler9, Hari S Sharma1

International Experimental CNS Injury & Repair (IECNSIR), Laboratory of Cerebrovascular Research, Dept. of Surgical Sciences, Anesthesiology & Intensive Care Medicine, Uppsala University Hospital, Uppsala University, Uppsala, Sweden, 1Dept of Neurosciences, University of Basque Country, Bilbao, Spain, 2Dept. Clinical Neurosciences, University of Medicine & Pharmacy, Cluj-Napoca, Romania, 3“RobNeuro” Institute for Neurological Research and Diagnostic, Cluj-Napoca, Romania, 4University of Maryland, Dept. of Pathology, Baltimore, MD, USA, 5Case Western Reserve Medical University, Dept. of Pathology, Cleveland, OH, USA, 6Anesthesiology, Massachusetts General Hospital, Harvard University, Boston MA, USA, 7School of Biomedical Engineering, Dept. of Biomaterials, Indian Institute of technology, Banaras Hindu University, Varanasi, India, 8Dept. Chemistry & Biochemistry & Biomedical Engineering, University of Arkansas, Fayetteville, AR, USA, 9Department of Pharmacology and Anesthesiology, University of Padua, Faculty of Medicine, Padua, Italy, 10Ever NeuroPharma, Oberburgau, Austria

PI04 - The effect of crenezumab on beta-amyloid toxicity–induced synapse loss, neurofibrillary tangles and cell death in human neurons in vitro

Ben Chih, PhD, Reina A. Bassil, BS, Shirley Ng, BS, Maureen Beresini, PhD
Genentech, Inc., South San Francisco, CA, US

Late Breaking Posters

LBP58 - Disease modifying therapy by targeting generic protein secondary structure of pathological oligomers at any stages of Alzheimer’s Disease models

Fernando Goni, PhD, Kryssal Herline, PhD, Mitchell Marta-Ariza, MSc, Frances Prelli, MSc and Thomas Wisniewski, MD

New York University School of Medicine, New York, USA
Theme II. New therapies and clinical trials

P5 - Therapeutic monitoring and prediction of the effectiveness of neurotrophic therapy in patients with mild cognitive impairment of the amnestic type
Gavrilo S.1, Volpina O.1, Kolythalov I.1, Ponomareva E.2, Seleznева N.2, Fedorova Y. B., Karaev D.1, A. V. Kamynin
Mental Health Research Center, Moscow, Russia, 1Institute of bioorganic chemistry M.M.Shemyakin and Ya.D.Archipov Russian Academy of Sciences, Moscow, Russia

P11 - 11β-hydroxysteroid dehydrogenase type 1 inhibitors pharmacological mechanism of potential therapeutic uses - a systematic review
Sarah Gregory1, John W. Keturley2, Tamara Miller2, Vincent S Ruffles3, Craig W. Ritchie1
University of Edinburgh, Edinburgh, UK, 1Acinogen Medical Ltd, Sydney, New South Wales, Australia

P20 - SUVN-502 - Baseline characteristics of phase 2a study in moderate Alzheimer’s disease - First-in-class Triple combination of SUVN-502+Donepezil+Memantine - A Promising new approach for the symptomatic treatment of Alzheimer’s Disease
Ramaprashna Nirogi, PhD1, Jyothsna Ravula, MS1, Satish Jetta, MTS1, Koteshwara Mudigonda, PhD1, Vinod Kumar Goyal, MS1, Santosh Kumar Pandey, MS1, Gopinadh Bhyrapuneni, PhD1, Renny Abraham, PhD1, Vijay Benade, MS1, Pradeep Jayarajan, PhD1, Anil Shinde, PhD1, John Ieni, PhD1 and Venkat Jasti, MS1
Discovery Research, Sween Life Sciences Ltd, Hyderabad, India

P23 - Efficacy and safety of triligulozole (BHV-4157) in patients with mild to moderate Alzheimer’s dementia: T2 PROTECT AD phase 2 study design
Irfan A. Qureshi, MD1, Karen Messer, PHD2, Kirsten Ericsson, Ph.D.2, Robert M. Berman, MD1, Carolyn Revta2, Tilman Oltersdorf, MD2, Brantho Huiss, MD1, Diane Jacobs, Ph.D.2, David Salmon, Ph.D.2, Doug Galasko, M.D.2, Thomas O. Obisesan, MD3, Neelum Aggarwal, MD4, Jacobo Mintzer, MD2, Judith Heidebrink, MD4, Amanda Smith, M.D.4, Miranda N. Reed, Ph.D.4, Holly C. Hunsberger, Ph.D.4, Lila Donahue1, Kimberly Gentile1, David A. Stoch, Ph.D.1, Vladimir Coric, M.D., MD1, Howard Feldman, M.D.7
Biohaven Pharmaceuticals, Inc., New Haven, CT, USA, 1Alzheimer’s Disease Cooperative Study, University of California at San Diego, La Jolla, CA, USA, 4Howard University, Washington, DC, USA, 5Rush University Medical Center, Chicago, IL, USA, 6University of California at San Francisco, San Francisco, CA, USA, 7University of Michigan, Ann Arbor, MI, USA, 8University of South Florida Health Byrd Alzheimer Institute, Tampa, FL, USA, 9Auburn University, Auburn, AL, USA

P56 - Gamma-secretase modulation has multiple anti-amyloidogenic effects in vivo
Bengt Winblad1,5, Gunnar Nordvall234, Ping Yan1, Johan Lundqvist234, Johan Sandin1234, Henrik Blivenståhl1, Henrik Zetterberg1, Rebecha Klintenberg1, Mats Ferm1, John R Ciritto2, Jin-Moo Lee1
AlzCure Pharma AB, Drug Discovery & Development, Huddinge, Sweden, 1AlzCure Foundation, Preclinical Research, Huddinge, Sweden, 2AstraZeneca R&D, CNS & Pain Aved, Södertälje, Sweden, 3Karolinska Institutet, Dept NVS, Div of Neurogeriatrics, Solna, Sweden, 4Washington University School of Medicine, Dept of Neurology, St Louis, USA, 5Karolinska University Hospital, Geriatric Clinical Trial Unit, Huddinge, Sweden, 6Karolinska University Hospital, Clinical Neurochemistry Laboratory, Milton, Sweden

P60 - Discovery of novel molecular chaperone modulators for the treatment of tau pathogenesis in Alzheimer’s disease
Rajnish Kumar, PhD1, Pavel Pavlov, PhD1, Bengt Winblad, MD, PhD1
Department of Neurobiology, Care Sciences and Society, Center for Alzheimer Research, Division of Neurogeriatrics, Karolinska Institutet, Solna, Sweden, 1Department of Geriatric Medicine, Karolinska University Hospital, Huddinge, Sweden

P79 - CogniXtra preventive treatment affords neuroprotection against amyloid beta 25-35 peptide-induced toxicity in mice
François J. Roman1, PhD, Johann Meunier1, PhD, Laura Ceolin1, PhD, Jean-Marie Butterlin2, MS, Guillaume Blivet3, MS, Jacques Touchon4, MD, PhD
1Amylia, Montferrier-sur-Lez, France, 2Health Optimization Devices B.V., Maastricht, Netherlands, 3www.cognixtra.com, 4Montpellier University, Montpellier, France

P84 - Clinical Development of AXS-05 (Dextromethorphan/Bupropion) for Agitation Associated with Alzheimer’s Disease
Henri Tabureau1, MD1, Amanda Jones, PharmD1, Cedric O’Gorman, MD1
Assume Therapeutics Inc, USA

P85 - Pharmacokinetics and safety profile of intravenous administration of Allopregnanolone in patients with early Alzheimer’s disease
Gerson D. Hernandez, MD, MPH1, Naoto Kono, MPH1, Claudia M. Lopez, BS1, Ron Irwin, PhD1, Kathleen Rodgers, PhD1, Jimmy Wu, PhD4, Rosario Mollo, PhD5, Sonia Pawluczty, MD1, Meng Law, MD, Wendy Mack, PhD1, Lon Schneider, MD, MS1, Roberta D. Brinton, PhD1
1Center for Innovation in Brain Science, University of Arizona, Tucson, Arizona, USA, 2Department of Preventive Medicine, Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA, 3School of Pharmacy, University of Southern California, Los Angeles, CA, USA, 4TOMO Pharmacometrics, LLC, San Mateo, USA, 5Department of Preventive Medicine, Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA, 6Department of Radiology, Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA

P88 - Posters Presentation
**P105** - SM07883, a novel DYRK1A inhibitor, reduced Tau pathology – discovery and preclinical development of a potential therapeutic for Alzheimer’s disease

Benoit Melchio, PhD1, Carolyn Lai1, Karen Duong-Poit1, Amanda Tijiro1, Lauren Pitzer1, Joshua Stewart1, Luis Dellamary1, Scott Anderson1, Brian Holliena, Chiao-Wen Chen, PhD1, Charlene Barroga, PhD1, Gopi Mittapalli, PhD1, Sunil KC, PhD1, Philippe Marchand, PhD1, and Yusuf Yazici, MD1

Samumell, LLC, San Diego, USA

**P106** - Apabetalone, a BET bromodomain inhibitor, suppresses inflammatory mediators in microglia and vascular endothelial cells that contribute to neurodegenerative disease

Ewelina Kulitowsk1, Emily Daze1, Sylvia Wasiat1, Dean Gilham1, Laura M. Tsujiwara1, Broothe Rahai1, Stephanie C. Stotz1, Christopher Halliday1, Ravi Jahagirdar1, Norman C. W. Wong1, Michael Sweeney1 and Jan O. Johansson1

Regeneron Corp, Calgary, AB, Canada; Regeneron Inc, San Francisco, CA, USA

**P107** - Clinico-radiological recovery of ARIA-like events in corticosteroid-treated CAA-ri patients: implications for the management of ARIA side effects of anti-amyloid immunotherapy

Fabrizio Piazza, PhD2,3,4, on behalf of the iCAβ International Network Collaborators and The CAA Study Group of the Italian Society of Neurology for dementia* Jacopo C. DiFrancesco1,2, Marialuisa Zedde1, Federica Angiulli1,2, Rosario Pascarella1, Roberto Marconi1, Francesco Perini1, Alberto Villarejo-GaIende1, Mario Crillo1, Berardino Orlandi1,2, Ihara Massuf1mi, Mehdi Touat1,2, Hagiwara Yut1, Juan F. Vázquez-Costa1, Massimo Cauli1,2, Shima Atsumishi1, Alessia Grossi1, Ricardo Nitrini1, Massimo Muscico1,2 *Main Network Collaborators:

1The inflammatory cerebral amyloid angiopathy and Alzheimer’s disease biomarkers (iCAβ) International Network; 2University of Milano Bicocca, Monza, Italy; 3The CAA Study Group of the Italian Society of Neurology for dementia (SINdem), Italy; 4University of Milano Bicocca, Monza, Italy; 5National Research Council, Segrave, Italy; 6Arcispedale Santa Maria Nuova (IRCICS), Reggio Emilia, Italy, Department of Neuroscience, Ospedale Maggiore della Carità, Genova, Italy; 7S. Bortolo Hospital, Vicenza, Italy; 8Hospital 12 de Octubre, CIBERNED, Madrid, Spain; 9Università della Campania “L. Vanvitelli”, Seconda Università degli Studi di Napoli, Italy; 10S.S. Filippo e Nicola Hospital in Avezzano, L’Aquila, Italy; 11National Cerebral and Cardiovascular Center, Osaka, Japan; 12Dana-Farber Brigham and Women’s Hospital, Boston, Massachusetts, U.S.A.; 13CMR UMR 7225, Sorbonne Universités, Paris, France & USA; 14St. Marianna University School of Medicine, Japan; 15Instituto de Investigación Sanitaria la Fe (IS La Fe), Valencia, Spain; 16University «G. d’Annunzio», Chieti, Italy; 17Kyoto University Graduate School of Medicine, Kyoto, Japan; 18O.U. of Neurology, ASST Cremona, Italy, 19University of São Paulo School of Medicine, São Paulo, Brazil

**P108** - Clinical Pharmacokinetics and Pharmacodynamics Demonstrate Once-Weekly CorplexTM Donepezil Transdermal System as a Therapeutic Alternative to Daily Oral Aricept

Bobby Singh, Corium International, Inc., 235 Constitution Drive, Menlo Park, California, USA

### Late Breaking Posters

**LBP59** - Triple therapy with SUVN-502, a 5-HT6 antagonist, donepezil and memantine in moderate alzheimer’s disease: Baseline patient characteristics in phase-2a study

Alireza Atri, MD, PhD1, Jeffrey L. Cummings, MD, ScD1, John Ieni, PhD1, Venkat Jasti, MS1, Ramatkhishna Nirogi, PhD1

1Banner Sun Health Research Institute/Banner Health, Sun City, AZ, USA, 2“Cener for Brain/Mind medicine, Department of Neurology, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA, 3Cleveland Clinic, Las Vegas, NV, USA, 4Discovery Research, Sven Life Sciences, Hyderabad, India

**LBP60** - Clinical polysomnography trial of suvorexant for treating insomnia in Alzheimer’s disease: trial design and baseline characteristics of participants

W.J. Herring, MD, PhD1, P. Ceesay, PhD1, E. Snyder, PhD1, D. Bliwise, MD1, K. Budd, BS1, J. Hutzelmans, BS1, J. Stevens, BS1, D. Michelson, MD1

1Merck & Co. Inc., Kenilworth, NJ, USA, 2Emory University School of Medicine, Atlanta, CA, USA

**LBP61** - Neuroprotective effect of a new photobiomodulation technique against amyloid Aβ25-35 peptide induced toxicity in mice might support a novel hypothesis for therapeutic approach of Alzheimer’s disease

Guillaume J. Blivet, MS1, Laura Auboyer, PhD1, Johann Meunier, PhD2, François J. Roman, PhD2, Jacques Touchon, MD, PhD1

1REGEnLIFE SAS, Montpellier, France, 2Mount Sinai KLAS, Montpellier-sur-Les, France, 3INSERM U1061, Montpellier, France, 4Neurology Department, University of Montpellier, France

**LBP62** - Interest of REGEnLIFE RGN530 photobiomodulation medical device for the treatment of Alzheimer’s disease: a double-blind, randomized sham-controlled trial to evaluate the safety and efficacy

Audrey Cabelle, MD, PhD2, Thibault Mura, MD, PhD1,2, Karim Bennys, MD1,2, Sophie Navucet, MS1, Martine Flores, MS1,2, Laura Auboyer, PhD1,2, Guillaume J. Blivet, MS1, Jacques Touchon, MD, PhD1,2

1Memory Research and Resources Center of Montpellier, Department of Neurology, Montpellier University Hospital, France, 2MUSE University, Inserm U1061, Montpellier, France, 3Department of Epidemiologic and Clinical Research, La Colombiere Hospital, Montpellier, France, 4REGEnLIFE SAS, Montpellier, France
CTAD 2018 would like to thank its privileged partners for their continued support of CTAD.

**Gold Sponsors**
General Information

Address
Fairmont Rey Juan Carlos I & Palacio de Congresos de Cataluña
Av. Diagonal 661 - 671
Barcelona
Spain 08028

Map of the conference hotel and congress center

Congress venue maps
Conference Room:
All sessions will take place in the Auditorium

Registration Information
Pre-registration: Avoid the rush and come pick-up your conference materials on Wednesday, October 24 starting at 1pm.

Registration desk opening hours:
• Wednesday, October 24 from 1pm to 7pm
• Thursday, October 25 from 7:30 am to 6 pm
• Friday, October 26 from 7:30 am to 5:30 pm
• Saturday, October 27 from 7:30 am to 4:00 pm

Coffee Breaks and Poster Sessions:
Breaks and poster presentations will be held in the dedicated area across from the auditorium. This year all posters for all the different themes will be presented during the entire conference. Meet our poster presenters during the coffee breaks. A poster assistance desk will be available at the entrance to locate the posters.

Lunches*: (only for attendees who purchased the lunch package) will be served next to the Poster Session in a dedicated area please present your badge at the entrance.
*Please note that there is no possibility of buying lunches onsite

Speaker Ready Room - Preview room - Hours of Operation
• Wednesday, October 24: 1pm to 6pm
• Thursday, October 25: 7:30 am to 6pm
• Friday, October 26: 7:30 am to 6pm
• Saturday, October 27: 7:30 am to 5pm

Networking coffee time: In addition to the regular coffee breaks we suggest that you enjoy a cup of coffee with your peers and increase your networking time around the conference starting times
• Wednesday, October 24: 3:15pm to 4:00pm
• Thursday, October 25: 7:45am to 8:30 am
• Friday, October 26: 7:45am to 8:30am
• Saturday, October 27: 7:45am to 8:30am and 3:00pm to 4:00pm

FREE WIFI AVAILABLE AT CTAD
Network: CTAD2018
Password: CTAD2018
Conference Mobile App

CTAD 2018 has its own Mobile App!

The App will be available for download on October 22, 2018 on the Apple App Store and Google Play (Search CTAD 2018) to be used on your mobile phone but also on large devices like an iPad or laptop computer.

The conference is right at your fingertips: discover the program, read the abstracts, learn more about our speakers, network with other participants and so much more!

Keep in touch

BARCELONA 2018

CTAD Congress
Phone: + 33 (0)4 67 10 92 23
Email: ctad@ant-congres.com
www.ctad-alzheimer.com

Follow us on

@CTADConference  CTAD Alzheimer  CTAD Conference

#CTAD18

www.ctad-alzheimer.com
December 4-7, 2019
SAN DIEGO, California
Hilton Bayfront San Diego

CTAD 2019
Clinical Trials on Alzheimer's Disease

Montpellier '08 / Las Vegas '09 / Toulouse ’10 / San Diego ’11
Monte Carlo '12 / San Diego '13 / Philadelphia '14
Barcelona '15 / San Diego '16 / Boston '17 / Barcelona '18

www.ctad-alzheimer.com
Email: ctad@ant-congres.com